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生素進行藥敏測試，包括tetracycline (T)(四環素)，erythromycin (E)(紅霉素)， 
clindamycin (D)(氯林可霉素)，gentamicin (G)(慶大霉素)，tobramycin (To)(妥布拉 
黴素)，ciprofloxacin (Ci)(環丙沙星)，netilmicin (N)(紫蘇黴素)，mupirocin (M)(百多 
邦)，fusidic acid (F), rifampicin (R)(威福仙)，co-trimoxazole (S) and chloramphenicol 
(C)(氯霉素)。其中312株典型具不同抗藥類型的MRSA菌株以[限制性內切酶 
和脈沖電游（PFGE)進行分類；此外，從5種脈沖電游類型及亞型中選取了 127株 
不同年份MRSA的典五菌株做下列各種分類測試，包括amplified fragment length 
polymorphism (AFLP), phage typing (•菌體分類)，coa gene polymorphism 及 
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Abstract 
Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen in many 
hospitals around the world and has become a major global concern. MRSA is usually 
resistant to multiple antibiotics. MRSA infections are associated with high morbidity 
and mortality and create a significant burden to health care resources. 
MRSA is endemic in most Hong Kong hospitals. The epidemiology of MRSA for the 
years 1988-1999 at Prince of Wales Hospital (PWH) was reviewed and indicated a 
changing pattern with a rise during 1995-99. This was associated with a 
disproportionate rise in MRSA bacteremia which was hypothesized to be likely due to a 
change in the strain types. The objectives of my project were: 1) to develop an effective 
typing system for MRSA and 2) to determine the relationship between strain distribution 
and MRSA incidence for the period of 1988 to 2000 at PWH, Hong Kong. 
The antimicrobial susceptibilities to tetracycline (T), erythromycin (E), clindamycin (D)， 
gentamicin (G)，tobramycin (To), ciprofloxacin (Ci), netilmicin (N)，mupirocin (M), 
fusidic acid (F)，rifampicin (R), co-trimoxazole (S) and chloramphenicol (C) were 
performed on 552 nonduplicate MRSA isolates collected between 1988—2000 at PWH. 
312 representative MRSA isolates with different antibiotic resistance patterns were 
typed by pulsed-field gel electrophoresis (PFGE) using Sma\ restriction enzyme. 127 
representative MRSA isolates selected from five PFGE types and subtypes between 
1988-2000 were further typed by amplified fragment length polymorphism (AFLP) and 
phage typing using 23 international phages, coa gene polymorphism and multilocus 
sequence typing (MLST) of the MRSA isolates were investigated. 
Two major PFGE types were obtained. PFGE type A and subtypes constituted 68% 
(211/312) of all the isolates and were present throughout the 13-year period. The 
majority of PFGE type A isolates had an antibiotic resistance profile TEDGToCi and 
belonged to phage type I. The PFGE type A isolates correlated to the high MRSA 
xiii 
isolation rate in ICU, medical and surgical units at the hospital. PFGE type B and 
subtypes constituted 13% (40/312) of all isolates and was only present from 1995-2000. 
These isolates had unique antibiotic resistance profiles TEGToCiNM, TEGToCiM, or 
TEGToCiNMF and belonged to phage type II. They were particularly associated with 
bacteremia in the special care baby and Bums units. However, results of the AFLP, coa 
gene restriction fragment digestion polymorphism and sequence suggested that the 
MRSA isolates with different PFGE types at PWH were closely related and belonged to 
one cluster. 
This study showed the establishment of a dominant MRSA clone (PFGE type A) and the 
appearance of a new MRSA strain in 1995 (PFGE type B) that explained in part the rise 
in MRSA cases and the disproportionate rise in MRSA bacteremia from 1995-2000 at 
PWH. Based on the results of PFGE, AFLP, coa gene polymorphism and MLST, MRSA 
isolates at PWH were closely related to the British epidemic MRSA, particularly EMRSA 
1 and 4. The use of a unique set of antibiotics in combination with PFGE may be applied 
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Chapter 1 Introduction 
Chapter 1 Introduction 
1.1 Biology of Staphylococci 
1.1.1 Taxonomy 
Staphylococcus aureus is a member of the Staphylococcus genus. It has a low GC 
content (30 to 38 mol percent) and belongs to the Bacillus/Clostridium group. It is 
phylogenetically classified in the Bacillus/Staphylococcus group and in the family of 
Staphylococcaceae89，i6i (www.ncbi.nlm.nih.gov/Taxonomy). It has been known as 
different names during the past including Staphylococcus aureus Rosenbach 1884， 
"Staphylococcus pyogenes aureus" Rosenbach 1884，"Staphylococcus pyogenes 
citreus" Passet 1885, "Micrococcus aureus" (Rosenbach 1884) Zopf 1885, 
"Micrococcus pyogenes" Lehmann and Neumann 1896 
(www.ncbi.nlm.nih.gov/Taxonomy). S. aureus had been previously misclassified 
into the genus of Micrococcus but it can be differentiated from the members of 
Micrococcus genus based on its low G+C content, being a facultative anaerobe and 
possessing teichoic acid in its cell wall.'^' Staphylococci are presently thought to be 
closely related to members of the Bacillus group. A study based on the whole 
genome sequence of S. aureus strain (N315) showed that there were up to 52% of 
fundamental proteins encoded by N315 genome similar to B. subtilis and B. 
halodurans. Therefore, it is believed that Staphylococcus and Bacillus share a 
89 common ancestor. 
The genus Staphylococcus currently includes 48 species and 17 subspecies 
(www.ncbi.nlm.nih.gov/Taxonomy). The species of S. aureus is the most studied one 
1 
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due to its clinical significance. 
1.1.2 Characteristics of S. aureus 
Staphylococcus aureus is a gram-positive coccus growing in clusters. It is a 
facultative anaerobe and is catalase positive and oxidase negative. It can tolerate high 
concentrations (up to 3.5 mol/L) of sodium chloride and can grow between 10°C to 
45°C. It produces triterpenoid carotenoids in its cell membrane and forms a golden 
QQ 
colour from fresh clinical specimen. It is distinguished from other species of the 
genus by the production of coagulase, clumping factor and deoxyribonuclease. It 
ferments a number of sugars, including mannitol, lactose, mannose, maltose, fructose 
and sucrose.93，i6i 
A variety of identification methods for S. aureus, including biochemical, 
immunological and molecular methods, have been used in clinical or research 
laboratories. The classic criterion for identifying S. aureus is the tube coagulase 
test. It is based on the ability of S. aureus to produce extracellular free coagulase 
that can interact with prothrombin in plasma to produce staphylothrombin. 
Staphylothrombin converts prothrombin into an active form that releases 
fibrinopeptides from fibrinogen to form fibrin clots.^^ 
Biochemical methods utilize the ability of the bacteria to produce certain enzymes 
and fermentation reactions may be used, as in the commercial kits API STAPH and 
ID 32 STAPH (bioMerieux, France). Selective media, such as mannitol salt agar, 
have been widely used for specific screening for S. aureus}^ 
Immunological tests have been used for the rapid identification of S. aureus. These 
2 
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include latex-agglutination tests which use various antibodies to detect multiple 
surface factors specific to S. aureus, such as the use of human fibronectin to detect 
the presence of cell wall polypeptide clumping factor; or the FC portion of human 
immunoglobulin G (IgG) for the detection of protein A�43 
Molecular methods, including PCR^ '^^ ^ and DNA probe hybridization methods,^^ 
detect genomic sequences specific for S. aureus. Molecular methods are rapid with 
high sensitivity and specificity and can be applied on subculture or directly to clinical 
specimens. 
S. aureus causes wide range of clinical disease in human including bactaeremia, 
wound infection, soft tissue abscesses, osteomyelitis, pneumonia, toxic shock 
syndrome, scalded-skin syndrome and food poisoning.24 
The major cell composition of Staphylococcus includes: the genome, cell membrane, 
cell wall, capsules, slime and exoproteins. The knowledge of the S. aureus 
genome89 is enabling rapid progress in the understanding of the transmission and 
virulence of the organism. Global gene regulators loci, such as sar and agr, 
important in the control of the balance of virulence factor expression versus 
colonization, are being elucidated.^ '^^ "^^  Genes for the MSCRAMMS (microbial 
surface components recognizing adhesive matrix molecules) and exotoxins 
Q 1 1 Q 
associated with virulence are being identified. ’ (Figure 1.1) Cell surface proteins 
such as protein A, fibronectin-binding protein and collagen-binding protein play 
important roles in staphylococcal pathogenesis in the evasion of host defense and 
1 1 Q 
promote attachment to host tissue. Exoproteins, such as the coagulase, 
haemolysins and exotoxins, such as enterotoxins A-J, are also important pathogenic 
3 
Chapter 1 Introduction 
factors of S. aureusKnowledge of these elements also contributes to their 
applications in the use for investigation of staphylococcal epidemiology. 
The staphylococcal cell wall plays an important role in maintaining the cytoplasmic 
function and integrity of the organism. Ninety percent of the weight of the cell wall 
is made of peptidoglycan (or murein) and teichoic acid. The monomeric component 
of peptidoglycan consists of two amino sugars (N-acetylglucosamine [GlcNAc] and 
N-acetylmuramic acid [MurNAc]) and ten amino acids (L-Ala, D-Glu, L-Lys, two 
D-Ala and five glycine). An enzyme, glycosyltransferase, present in the cytoplamic 
membrane polymerizes murein monomers to produce peptidoglycan single chains. 
Penicillin-binding proteins (PBPs) are transpeptidases which allow cross-linkage 
between the new and the pre-existing peptidoglycan chain (Figure 1.2) to form the 
cell wall structure. 
S. aureus typically contains four penicillin binding proteins (PBPs 1 to 4) and 
methicillin-resistant S. aureus (MRSA) has an additional penicillin-binding protein 
(PBP 2' or PBP 2a).30’63,64’66’93，154’161 
Teichoic acid is a water-soluble polymer, 10-40 units in length and it attaches to 
peptidoglycan. The functions of teichoic acid include acquisition and localization 
of metal ions and control of the activities of autolytic enzymes. ^ ^^  
4 
Chapter 1 Introduction 
I A Surface proteins Secreted proteins 
(exponential-growth phase) 《stationary phase) 
I 
i 
Coaguiase Enterotoxin B ！ 
Pr�•仏 秦 - j T S S T - � ： 
S ： ^ � ” Peptido 如 n Capsule 
^ Stationary j P i m , / M t o i B teichoic • 
I Collagen- ffi f Ph 肪 y ^ / ^ ^ ^ ^ ^ acid 
I ^ , I f I ( m ^ 
y : % Exponential- m l p'rote'in " ^ E f e f e M M - Cross-linking 
Clumping factor j 
Cell-wall - Repeats Ligand-binding 
anchoring domain 
domain 
Figure 1 • 1 Structure of S. aureus (reproduced from reference^�） 
The synthesis of many cell surface proteins is dependent on the growth phase as well 
as the control of regulatory genes such as agr. Panel B and C show cross-sections 
of the cell envelope. Many of the surface proteins have a structural organization 
similar to that of clumping factor, including cell-wall-anchoring domain, repeated 
segments of amino acid and ligand-binding domain (panel C). 
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Figure 1.2 Assembly of peptidoglycan viewed from outside of the cell. 
(Reproduced from reference^ )^. In blue is the cytoplasmic membrane. 
Glycosyltransferase polymerizes the murein monomer to produce a nascent 
peptidoglycan single chain. Penicillin-binding protein (PBP) grasps at the 
D-alanyl-D-alanine residues of stem peptide and cleaves in between the residues to 
the residues to ligate the penultimate D-alanine to the pentaglycine of the 
neighboring peptidoglycan chain. 
6 
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1.2 Methicillin-resistant Staphylococcus aureus 
(MRSA) 
1.2.1 Description of MRSA 
Methicillin-resistant Staphylococcus aureus (MRSA) is identified as a S. aureus 
strain resistant to 1 |ig of oxacillin on disk diffusion test� or equal or greater than 4 
mg/L on MIC test.^ ^ Historically, the name methicillin-resistant Staphylococcus 
aureus was given to the group oi Staphylococcus aureus which showed resistance to 
methicillin, a semisynthetic penicillin. Oxacillin is now used to detect the resistance 
of S. aureus to p-lactams because oxacillin is more stable during storage and has a 
higher potential to detect the heteroresistant strain.^ The expression of resistance is 
usually heterogeneous and is affected by many factors including the inoculum size, 
incubation time and temperature, pH and salt concentration of the medium.^^ Along 
with the development of molecular technology, a PGR method for detecting the 
mecK gene, encoding for methicillin resistance in Staphylococcus aureus, is 
recognized as the "gold standard" for defining the classical staphylococcal 
methicillin resistance. 
1.2.2 Antibiotic Resistance of MRSA 
MRSA is multiply resistant, being resistant to all (3-lactam antibiotics, including all 
penicillins, cephalosporins and carbapenems, and often other antimicrobial agents, 
such as aminoglycosides, macrolides, clindamycin, and tetracycline. '^^ '^^ ^ MRSA 
employs several resistant mechanisms against different classes of antibiotics. These 
mechanisms can be categorized into two types: 1) resistance to p-lactams and 2) 
resistance to antibiotics other than p-lactams. 
7 
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1.2.2.1 Resistance to p-lactam Antibiotics 
MRSA is resistant to all P-lactams because of their capability of producing 
P-lactamase and PBP2a. 
1.2.2.1.1 Production of P-lactamase 
Most of the MRSA produce a penicillinase, which hydrolyzes the P-lactam ring and 
disables the function of all (3-lactamase-labile penicillins, such as penicillin G. The 
production of p-lactamase is encoded by blaZ gene that is present on a transposon 
(Tn552) and is regulated by the blal-blaRl systems which are often found on large 
plasmids.5o 
1.2.2.1.2 Penicillin-binding Protein PBP2a 
MRSA produces a specific penicillin-binding protein, PBP2a (or PBP2，），that has a 
low affinity for all p-lactam antibiotics, including a variety of semisynthetic 
penicillins such as methicillin, carbapenems and cephalosporins. This protein is a 
transpeptidase which allows continued cell wall formation when other PBPs, PBP 1 
to 4，are inactivated by the presence of p-lactams (Figure 1.3). 
PBP2' is encoded by a chromosomal gene mecA, which is part of the mec 
determinant.3o，64’ 126’ 154 The mec determinant is an externally acquired element from 
MSSA.37 It locates between the genes spa, encoding protein A, and purh, encoding 
C(\ QQ  
a protein involved in purine synthesis. ， The essential structure of the mec 
element includes mec A gene and a variable segment of 3' DNA.50’74 The expression 
of mecA gene is regulated by mecl, encoding MecRl, which is an inducer protein of 
methicillin resistance, and mecRl, encoding Mecl, which is a strong repressor of 
methicillin resistance. These three genes form the mecA gene complex 
8 
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Figure 1.3 Action of Beta-lactam (reproduced from reference^ )^ 
Beta-lactam (purple double cubes) is a structural analogue of D-alanyl-D-alanine 
residues. It inactivates S. aureus PBP (in red), but cannot bind to PBP2a (in green) 
with high affinity. Therefore, MRSA can continue peptidoglycan synthesis in the 
presence ofbeta-lactams whereas methicillin-susceptible S. aureus cannot. 
9 
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{mecI-mecRl-mecA)}^^ Meek gene is carried by the staphylococcal cassette 
chromosome mec (SCCwec), an exogenous mobile DNA with the size of 21-67 kb 
and integrated in the chromosome of MRSA at a unique site {attBscc). The 
SCCmec also carries a set of recombinase genes, ccrK and ccrB, which involve the 
83 
integration and excision of SCCmec within the S. aureus chromosome. 
The origins of SCCmec are unknown; but recent studies supported the hypothesis of 
horizontal transfer of the mec element among S t a p h y l o c o c c i . F o u r types of 
^CCmec have been identified.^ '^"^ '^^ ^ Type I SCCmec is identified in MRSA (NCTC 
10442) isolated in England and Denmark in 1960s, also known as the archaic clone, 
and in the Iberian clone in 1989. Type II SCCmec is found in MRSA (N315) 
isolated from Japan and EMRSA 16 from UK. Type III SCCmec is present in 
MRSA isolated from Europe in the 1980s, including EMRSA 1, 4, 7, 11 and the 
Brazilian and Hungarian clones. Type IV SCCmec is found in a Pediatric clone 
isolate in 1990s, EMRSA 2, 6, 10，15 from UK and the recent community-acquired 
MRSA strain.75，96’iio The structures of the four types of SCCmec are shown in 
Figure 1.4. 
These four types of SCCmec carry different antibiotic resistance determinants. 
Both type I and type IV SCCmec contain no antibiotic resistant genes except meek 
gene. Type II and type III SCCmec have multiple resistant genes, including resistant 
genes for erythromycin, tobramycin, bleomycin, tetracycline, cadmium and 
mercury.67’73 MRSA strains belonging to SCCmec type I and IV, such as the 
archaic clone and community-acquired MRSA strain, are more susceptible to 
antibiotics. MRSA strains belonging to SCCmec type II and III, such as the 
Japanese strains and Brazilian clone, show more resistant properties. 
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1.2.2.1.3 Borderline Methicillin Resistance (BORSA or MODSA) 
Some strains of S. aureus show borderline (BORSA) or moderately resistant 
(MODSA) to methicillin. This phenomenon is seen in the following situations: 1) 
overproduction of p-lactamase, 2) production of an p-lactamase that hydrolyzes 
methicillin, 3) alterations in the binding capacity of the regular PBPs, 4) 
overproduction of one of the PBPs, and 5) heterogeneous resistance of mecA. These 
strains of MRSA are clinically less relevant.�，，;。 
1.2.2.2 Resistance to Antibiotics other than p-lactams 
Besides p-lactams, MRSA is resistant to multiple antibiotics by various resistance 
mechanisms. These mechanisms include chemical modification of the 
antimicrobial agents, production of an alternative enzyme, modification of the target 
binding sites, pumping the antimicrobial agents out and sequestration of the agent by 
eff lux ."9 Resistance by these including to aminoglycosides, macrolides, 
chloramphenicol, tetracycline, mupirocin, rifampicin, fusidic acid and trimethoprim 
and sulfonamides has been repor ted ." 9 
The resistance determinants are often encoded by genes that are located on 
transposons and insertion sequence present on the bacterial chromosome or plasmids. 
For example, aminoglycosides, such as gentamicin and streptomycin, are inactivated 
by aminoglycoside-modifying enzymes that acetylate and phosphorylate these 
antibiotics. These enzymes are encoded by aacA-aphD gene that are found within 
transposon Tn4001. Macrolides, such as erythromycin, are inactivated by 
methylation of 23 S rRNA which reduces the affinity between the ribosome and the 
macrolides. The enzyme responsible for erythromycin resistance is encoded by 
the ermA gene that is encoded on the transposon Tn554. Chloramphenicol is 
11 
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Figure 1.4 Structure of Four SCCmec Types (reproduced from reference^ )^ 
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inactivated by a chloramphenicol acetyltransferase enzyme (CAT) that acetylates the 
antibiotic. This enzyme is encoded by the cat gene located on variety of 
staphylococcal plasmids, such as pC194, pC221 and pC223. Mupirocin is 
inactivated by production of a modified isoleucyl tRNA synthetase that is encoded 
by mupA found in 
Several resistance genes are inserted and accumulated in SCC/wec, proposed to be an 
antibiotic-resistance island, around the mecA gene (Figure 1.5). For example, the 
spc gene encoding for spectinomycin resistance and the errtiA gene encoding for 
erythromycin resistance present within Tn554 are located at the upstream region of 
mecA. Moreover, plasmid pUBllO which is located downstream of mecA, 
IS431 that carries the aadD gene encoding resistance to kanamycin and 
tobramycin.73，74 
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Figure 1.5 Drug -resistance gene in the SCCmec of MRSA (N315). 
(reproduced from reference?]). Drug-resistance genes present in N315-SCCmec 
(type II). A transposon, Tn554 (green) located upstream in the transcriptional 
direction of the mecA gene contains an erythromycin-resistance gene (erwA)(blue) 
and a spectinomycin-resistance gene (spc) (blue) in addition to three transposes 
genes, tnpA, B, and C. Transposase orf. B. subiilis-denwQd plasmid, puBllO 
(pink), is integrated between the two copies of IS431 on SCCmec and containing 
resistance genes including oadD (blue), kanamycin nucleotidyltransferase gene, and 
ble (blue), a bleomycin-resistance protein gene. 
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1.2.3 Epidemiology of MRSA 
1.2.3.1 Clinical Significance of MRSA 
MRSA is one of the most common pathogens causing serious nosocomial infection 
in hospitals w o r l d w i d e . ^ T h e mortality rate of MRSA infection is high, 
between 16-56%, and mainly associated with aged patients and patients with 
underlying disease.36’84’i39’i46，i52 mRSA are spread person-to-person, often by 
cross-contamination from colonized health care workers or chronically infected 
patients. MRSA infections significantly increase the burden to the health care 
systems. Costs of controlling MRSA infections are expensive; direct attributable 
costs include extended stay at hospital, cost of diagnostic procedures and 
management of in fec t ion 48’57 Other intangible costs including loss of patient's 
income, associated morbidity and mortality, are significant. Risk factors for MRSA 
transmission include characteristic of the strains, antibiotic exposure, patient 
populations at risk, and infection control measures in the i n s t i t u t i o n . � 
Vancomycin has been an effective antimicrobial agent against MRSA. However, 
since 1997，MRSA strains with intermediate vancomycin resistance (VISA) have 
been reported in Japan,^^ United State,France,122 Korea,^^ South Africa^ and 
Hong K o n g . 162 In addition, infections caused by MRSA are no longer limited to 
acquisition as hospital infection, community-acquired MRSA infections have been 
reported beginning from the early 1990s from many countries, including Australia, 
New Zealand，i03 the United States^ Canada，！ and Saudi Arabia.^^ 
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These new community-acquired MRSA strains are more susceptible to antibiotics 
and often only resistant to methicillin.^^'^^ These strains carry fewer resistance 
determinants and may promote their ability to colonize humans and spread within the 
community. 96 
1.2.3.1.1 Evolution of MRSA 
MRSA was first reported in England in 1961/8 ^^^ yg^r after the introduction of 
methicillin. By 1968, increasing numbers of MRSA isolates and outbreaks were 
reported from many European countries including United Kingdom/" Denmark,^^^ 
France,29 and Switzerland]4 Other countries reporting MRSA around this time 
included Australia/^^ India/Poland,21 Turkey^^ and United State.^^ MRSA was 
thought to be evolved from methicillin-susceptible S. aureus strain through 
acquisition of the SCCmec determinant.^ '^^ '® Lencastre and her group^^ studied the 
relationship between early methicillin-resistant and susceptible S. aureus strains 
recovered from Denmark and MRSA strains from the UK. Her group found that all 
these isolates were belonged to the same phage group (group III and / or 83A) with 
the same antibiotic resistance pattern (penicillin, streptomycin and tetracycline) but 
susceptible to methicillin. They suggested that the early Danish MRSA strains 
might have evolved from the MSSA strain by acquiring the mecA gene.^^ This 
suggestion was further confirmed by molecular typing with MLST, PFGE, and spaA 
typing.37 The Danish MRSA strain and the UK MRSA strains also had the same 
meek, polymorph {Cla-mecA polymorphism II)，showed low-level and heterogeneous 
methicillin resistance (MIC 6-25 |ig/ml), and had the same PFGE type.^^ Moreover, 
these Danish and British MRSA strains might represent the archaic clone of MRSA 
that spread among the European countries.^ '^^ '^^ ^® 
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Hiramatsu and colleagues studied the structure of the mec complex of pre-MRSA 
strains recovered in the 1980s from Japan and the clinical MRSA s t r a i n " They 
found that both the methicillin sensitive strain and the MRSA strain possessed the 
class A mec complex. The pre-MRSA strain has an intact mecl gene with 
repressed methicillin resistance but the MRSA strains have either type II or type III 
^CCmec and have mutation in mecl gene or at the operator region of the mecA gene, 
where the Mecl repressor protein was thought to bind.^^ 
1.2.3.1.2 Epidemiology of MRSA Worldwide 
After the first appearance of MRSA in 1960s, a decline in MRSA cases was observed 
in the 1970s. However, re-emergence of MRSA strains occurred the in early 1980s 
in the United Kingdom,49 Australia/^^ the Irish Republic,^^ and the United S t a t e s ? 
The MRSA isolates recovered during the second wave were resistant to more 
antibiotics such as gentamicin, trimethoprim, ciprofloxacin and mupirocin. They 
were phage grouped into group III and commonly included phage 84，85 and 
The emergence of these multi-drug resistant strains at different times followed the 
introduction of these antibiotics. 
In the U.K., sixteen epidemic strains were identified. EMRSA 1 emerged in the 
London hospitals in 1981 and gradually spread around South-East England as well as 
the Irish Republic and Australia^^ and later to Spain in 1992， A series of other 
EMRSA, 2-14，were found elsewhere in the U.K. between 1980 and 1986. In the 
late 1980s, EMRSA 3 was the predominant strain in UK. Until 1991 when EMRSA 
15 appeared and was followed by EMRSA 16.48 Currently, EMRSA 15 and 
EMRSA16 are the two major epidemic MRSA strains found in England?; and are 
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associated with severe infections. The characteristics of these EMRSA strains are 
listed in Table 1.1. 
A dramatic rise in the incidence of MRSA isolates was reported in many countries 
since the 1980s. For example, the National Nosocomial Infections Study showed 
that the isolation rate of MRSA increased 26.6 % (2.4%-29%)between 1975 and 
1991 in the United States;^3 a survey in Italy also showed that the isolation rate of 
MRSA increased 20% (6%-26%) between 1981 and 1986.135 Moreover, the 
frequency of MRSA increased 27% (40%-67%) between 1987 and 1992 in a 
Shanghai Hospital. In Portugal in a multicenter study of 10 Portuguese hospitals 
performed during 1996-1997, the prevalence of MRSA was estimated as 48%, one of 
the highest in Europe.'®^ Besides the countries mentioned, MRSA was also 
reported in many other regions including the Middle East, Africa, Russia, South 
America, and the Far East.:� Globally, five pandemic MRSA clones have been 
identified. They are the Iberian c l o n e , B r a z i l i a n c l o n e , H u n g a r i a n c l o n e / � 
New York/Japan clone^ '^"^ ^ and pediatric clone.^ '^'^ ® The Iberian clone was first 
reported in 1989 in Spain and later in Portugal, Italy, the UK, Germany, Belgium, 
Switzerland, France, Czech Republic, Poland, and the USA.^ ，應’i09’i3i The 
Brazilian clone was first identified in 1992 in Brazil and subsequently spread to 
Portugal, Argentina, Uruguay, Chile, and the Czech Republic.4’42’i02’i08’i09，i48 The 
Hungarian clone was found among hospitals in Hungary and later in Taiwan."^ ®''®^ 
The New York/Japan clone was reported in a number of states in the U.S., including 
New York, New Jersey, Pennsylvania, and Connecticut, and Tokyo in Japan.4’_ 
The Pediatric clone was first described in a pediatric hospital in Portugal in 1992 and 
was then reported in Poland, USA, Argentina, and Colombia.9’4i’59’•’The 
distribution of these international clones is shown (Figure 1.6) and their 
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Table 1.1 Characteristics of epidemic MRSA in the UK 
Phage type Antibiotic Resistance Pattern 
EMRSA 1 85/88A/923 P T E (K) (G) S 
EMRSA 2 52/52A/79/80/95/85 P E 
EMRSA 3 75/83A/83C P E (K) (G) (N) (Ci) (S) 
EMRSA 4 85/90/923 P T E S 
EMRSA 5 79/6/42E/47/54/77/84/81 P T K G Rif 
EMRSA 6 90/923 P t E K N B a S 
EMRSA 7 85 P T E S 
EMRSA 8 83A/83C/923 P T S 
EMRSA 9 77/84/932 P T E K G S 
EMRSA 10 29/75/77/83A/85 P T E K G S 
EMRSA 11 83A/84/83C P T E K G N B a S 
EMRSA 12 75/83A/83C/932 P T E K N F S 
EMRSA 13 29/6/42E/47/54/77/81/83C P T K G N B a F S 
EMRSA 14 29/6/47/54/90/923 P T K G N F S 
EMRSA 15 75wk P (E) Ci 
EMRSA 16 75/77/83A83C P E (K) (G) (N) Cip 
Modified data from the reference"^^ 
Phage type was done at lOOx RTD 
Antibiotic Resistance pattern: 
Ba (Bacitracin), Cip (Ciprofloxacin), E (Erythromycin), F (Fusidic acid), G 
(Gentamicin), K (Kanamycin/Tobramycin), N (Neomycin), P (Penicillin), Rif 
(Rifampicin), S (Streptomycin), T (Tetracycline) 
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Figure 1.6 International spread of the pandemic MRSA clones 
(Reproduced from reference^ 
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characteristics are listed (Table 1.2.) 
Comprehensive molecular analysis using various typing methods, including 
pulsed-field gel electrophoresis, mecA gene polymorphism digested with Clal, 
transposon Tn554 insertion patterns, multilocus-sequencing typing and spaA typing, 
has recently been performed on these international and archaic clones in order to help 
elucidate further the relationship and lineages of the MRSA in this pandemic spread 
in the last few decades. The results are shown in Table 1.2. 
Based on these profiles, it was concluded that the archaic clone and Iberian clone 
were closely related for they had the same genetic background, same spak type and 
same SCCmec type, "o Moreover, the Brazilian clone and the Hungarian clone were 
also closely related for the same reason. The NY/Japan clone and Pediatric clone 
were also related but they had different SCCmec type. Based on MLST profiles and 
SCCmec typing only the EMRSA 1，4，11 were indistinguishable from the 
representative of the Brazilian clone^^ whilst EMRSA 15 and 16 have unique MLST 
types although EMRSA 16 and NY/Japan as well as EMRSA 15 and the Pediatric 
clone had the same SCCmec (type II & IV respectively) but different MLST profile. 
1.2.3.2 MRSA in Hong Kong 
In Hong Kong, MRSA is considered to be endemic in the local hospitals.^^ In the 
early 1990s, 25-30% of clinical S. aureus isolates were MRSA.^^ The most recent 
study has shown that the prevalence rate of MRSA was 69.8% in Hong Kong, the 
highest among Asia-Pacific region. ^ ^ 
A previous study at the Prince of Wales Hospital (PWH), Hong Kong, documented 
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the prevalence rate of MRSA from different wards including medicine (35%), 
surgery (20%), SCBU (15%), pediatric (15%) and orthopedics (15%).^^ The Prince 
of Wales Hospital (PWH), Hong Kong is a 1350-bed teaching hospital that serves a 
population of approximately a million (1/6出 of total Hong Kong's population) in the 
New Territories East region. Most of the MRSA isolates cultured in 1985 were 
resistant to gentamicin, tetracycline, erythromycin and some of them were also 
resistant to chloramphenicol, trimethoprim, rifampicin and fusidic acid^^ and plasmid 
typing indicated they were heterogenous.^^ The emergence of 
ciprofloxacin-resistant MRSA strains appeared in 1988 and the incidence of the 
strains rose dramatically by 1993. Phage typing performed indicated heterogenous 
groups were involved.�34 
Between the years of 1989 to 2000，the incidence of new cases of MRSA fell from 
0.81/100 deaths and discharges (D&D) in 1989 to 0.33/100 D&D in 1993 but then 
rose back to 0.53/100 D&D in 1999 (Figure 1.7). MRSA bacteraemia was less than 
0.04% of D&D in 1989; but a disproportionate rise in MRSA bacteraemia occurred 
from 1995 to 1999 and reached 0.045% D&D (Figure 1.8). 
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Table 1.2 Molecular typing of pandemic MRSA clones, 
(modified from reference's，"®) 
Clonal spaA MLST Genetic SCCmec Antibiotic 
Type Type Profile Background Type Resistance Profile 
Archaic MBQBLO 3-3-1-1-4-4-16 A1 I O P 
Iberian MBQBLO 3-3-1-12-4-4-16 A2 lA O P D E G S p T e 
Brazilian KAOMQ 2-3-1-1-4-4-3 A3 IIIA O P D E G T e S 
Hungarian KAOMQ 2-3-1-1-4-4-3 A3 III O P D E G S p T e 
NY/Japan DMGMK 1-4-1-4-12-1-10 B II O P D E G S p T e 
Pediatric DMGMK 1-4-1-4-12-1-10 B IV O P G ( E ) 
EMRSA15 7-6-1-5-8-8-6 IV O P (E) Ci 
EMRSA16 2-2-2-2-2-3-2 II O P E (K) (G) (N) Ci 
Oxacillin (O), Penicillin (P)，Clindamycin (D), Erythromycin (E), Gentamycin (G), 
Spectinomycin (Sp), Tetracycline (Te)，Ciprofloxacin (Ci), Kanamycin (or 
Tobramycin) (K), Neomycin (N) 
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Figure 1.7 New MRSA cases by deaths & discharges at PWH, 1989-1999 
(Reproduced from reference^"^) 
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Figure 1.8 MRSA bacteremia by deaths & discharges at PWH, 1989-1999 
(Reproduced from reference^"^) 
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1.3 Strain Typing for MRSA 
Strain typing distinguishes different strains of the same species according to their 
similarity by multiple characteristics. Strain typing is useful in outbreak 
investigation and surveillance studies. This is based on the hypothesis that a set of 
isolates with similar characteristics are from one common precursor and they are the 
causative agents of the outbreak or they form an epidemiological cluster that 
becomes prevalent in the population over extended periods of time. The utilization 
of strain tying is then able to differentiate the outbreak or epidemic strains from the 
endemic or sporadic strains.7’i44 
Strain typing methods fall into two categories: phenotypic and genotypic typing 
methods. Phenotypic methods are based on the physical characters that are the 
product of gene expression, such as biochemical profiles, bacteriophage type and 
antimicrobial susceptibility profiles. However, any conditions that affect gene 
expression, including changes in growth conditions, growth phase, and spontaneous 
mutation will alter the results of these typing methods. Genotypic typing methods 
study the genetic structure of an organism including polymorphisms in DNA 
restriction patterns of a gene or the chromosomal DNA and the sequence variation of 
individual genes. Genotypic methods are less affected by external conditions but 
will also vary due to changes of the genetic structure including insertions or deletions 
of DNA into the chromosome, the gain or loss of extrachromosomal DNA, or 
random mutations that may create or eliminate restriction endonuclease sites. 
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The selection of typing method is based on the epidemiological situation in the study, 
but the methods chosen depend on the typability, reproducibility and discriminatory 
power, ease of interpretation and ease of performance of the method concerned. 
Often, methods that require subjective analysis and expertise to interpret the results 
are less favorable as variations among performers and laboratories tend to be high. 
A typing method that uses simple techniques, uses less expensive equipment and 
gives discriminatory and easy to interpret results is more favorable for wide use in 
different clinical settings.7’i49’i50 八 comparison of the methods in terms of 
typability, reproducibility, discriminatory power, ease of interpretation and ease of 
performance is summarized in Table 1.3. 
Strain typing for MRSA has proven to be challenging as most of the MRSA strains 
are derived from a relatively small number of clones and exhibit limited genetic 
d ive r s i t y . 87 Therefore, methods with high discriminatory power are necessary. 
Both phenotypic and genotypic techniques have been used for typing MRSA. Some 
commonly used methods for typing MRSA are discussed in the following sections. 
1.3.1 Phenotypic Methods 
The most commonly used phenotypic methods for typing MRSA are antimicrobial 
susceptibility testing and bacteriophage typing. 
1.3.1.1 Antibiotic Susceptibility Test 
Antimicrobial susceptibility testing classifies the bacterial strains according to their 
resistance patterns to a panel of antibiotics. It is inexpensive and easy to perform. 
Antibiotic resistance patterns associated with certain epidemic strains, such as the 
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EMRSA and the international clones has been d e s c r i b e d . ！丨’卯，!� Therefore, a 
specially designed panel of antibiotics for susceptibility testing may increase the 
discriminatory power and will be able to distinguish epidemic and sporadic strains. 
The disadvantages of this method are poor discriminatory power and low 
reproducibility. Loss or gain of plasmids carrying resistance genes will change the 
antibiotic susceptibility pattern of an isolate. Lastly, the expression of antibiotic 
resistance in vitro may be affected by culture conditions, such as pH of the media, 
inoculum size and incubation time and temperature.^^ Therefore, two isolates from 
the same clone may have different antibiograms and the same isolates may produce 
different patterns when tested at different times. 
1.3.1.2 Bacteriophage Typing 
Bacteriophage typing was established by Blair and Williams in 1961 and is based on 
the susceptibility of S. aureus isolates to the lytic action caused by a set of 
bacteriophages. 17 The international set of bacteriophage includes 23 phages that are 
categorized into four different lytic groups ( I , I I， I I I & V ) plus 2 additional p h a g e s ] i 6 
Lytic group I includes 5 phages (29’ 52，52A, 79，80). Lytic group II includes 4 
phages (3A，3C, 55, 71). Lytic group III includes 10 phages (6, 42E, 47，53, 54，75, 
77，83A，84，85). Phage 94 and 96 belongs to lytic group V. Phage 81 does not 
belong to any particular lytic group; but, it is considered to be associated with lytic 
group I. Phage 95 is not placed in any lytic group; but, strains lysed by phage 95 
belong to lytic group III. Phage 42D belongs to lytic group IV but is not included 
in the basic phage set. The susceptibility of a strain to these phages is usually 
group-related. That means if a strain reacts with one phage of a lysogenic group, it 
has higher tendency to react with other phages within that group. Moreover, strains 
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reacting with lytic group I also tend to react with lytic group III and cross-reaction 
among groups I and II or group II and III are less common. Strains lysed by lytic 
group V are not usually lysed by any other lytic group.'^^ 
Phage typing is performed using Ix RTD (routine test dilution); but most of the 
MRSA are nontypable with this dilution. Therefore, as increase in phage 
concentration to lOOx RTD is necessary. ^ ^ However, increasing the phage 
concentration may increase the typability of the method, testing with high 
concentration of phages (lOOOx RTD) results in too many nonspecific inhibition 
reactions. Thus, typing utilizing lOOOx RTD must be interpreted with caution. 
Phage typing has been used for decades, especially in England. It is a relatively 
good phenotypic method but has its limitations. Some S. aureus strains are 
non-typable by this method^ ^^ '^ "^ ^ and extra phages have been added for typing 
MRSA in other c o u n t r i e s . ⑴？’！之？ requires technical skills to minimize laboratory 
variation in interpretation and it is laborious and time consuming for maintaining the 
phage system. 
1.3.1.3 Multilocus Enzyme Electrophoresis 
Multilocus enzyme electrophoresis is a protein-based typing method. It depends on 
the variation in mobility of certain metabolic enzymes in starch gel.i45’i55 has 
good typability and reproducibility^ but only moderate discriminatory power can be 
obtained.^ This method is very useful in population studies? but it is not practically 
used in the clinical setting for it is labor intensive and time c o n s u m i n g ] 49 
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1.3.2 Genotypic Methods 
Many genotypic techniques for typing MRSA have been established including 
pulsed-field gel electrophoresis (PFGE)/^ '^ ® '^^ '^ analysis of coaguiase gene 
p o l y m o r p h i s m s ? � ’ 138,141 a n d repeat variation in the protein A g e n e，5 6 ’ i " ’ i 4 0 binary 
typing, 157 random amplification of polymorphic DNA'^^ and plasmid a n a l y s i s . i 4 5， i 4 9 
Amplified fragment length polymorphism (AFLPfo"! and multi-locus sequence 
typing (MLST)52’54 have recently been introduced. Genotypic typing methods 
usually have higher discriminatory power than phenotypic typing methods; but they 
require expensive equipment and technical skills to perform the tests and computer 
software for analysis of the results. 
1.3.2.1 Analysis of Chromosomal DNA 
1.3.2.1.1 Pulsed-field Gel Electrophoresis (PFGE) 
PFGE is considered to be the "gold-standard" for typing MRSA due to its high 
discriminatory power and typability.34’i06,i23’n2,i36 was developed by Schwartz 
and Cantor in 1984^^ ^ and it has been widely adopted in many laboratories for 
epidemiological s tudies]55 This technique separates large DNA molecules 
(50-750-kb) embedded in agarose by alternating the orientation of the electric field 
during e lectrophoresis"45 Chromosomal DNA is digested using a rare cutter, such 
as Smal, to generate DNA fragments which gives the DNA profile for comparison. 
Normally simple patterns containing 10 to 30 fragments between sizes of 10 - 800 
kb are produced. Visual comparison of the fingerprint profile produced by the sizes 
of the fragments and the positions of the bands are compared within the same gel and 
interpreted according to Tenover et. al/^^ If a large number of strains are 
examined, computer software analysis based on the reference standard included in 
each gel for normalization is used. 
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PFGE has proved to be superior to other typing methods34’i06,i32’i36 ^^^ has been 
extensively used in epidemiological studies of MRSA.^ '^'® '^'^ ^ However, it has its 
drawbacks particularly in their lack of standardization between laboratories and 
difficulties in interpreting the profiles.！^之 Many studies have u s e d Tenover's 
criteria for interpreting PFGE result which is strictly useful for outbreak 
investigations of a small number of isolates. Modifications in interpretation often 
have to be applied for surveillance studies and detailed guidelines would be 
necessary to improve standardization of interpretation between laboratories. 
1.3.2.1.2 Amplified Fragment Length Polymorphism (AFLP) 
Amplified fragment length polymorphism detection is a DNA fingerprinting method 
incorporating enzyme digestion of chromosomal DNA and PCR techniques. It was 
designed by Zabeau and VosJ^^ The combination of two restriction enzymes, one 
rare cutter and one frequent cutter, generates 40-75 fragments ranging in size of 
50-450 bp. It demonstrates good reproducibility and typability with wide range of 
application to eukaryotic and prokaryotic organisms.'^ It has been proved to be 
able to type several gram positive and gram negative bacteria such as 
Streptococcus,Acinetobacte/^秘 and many others.77，!3�a research group 
from the Public Health Laboratory in England also applied the fluorescent AFLP 
method to MRSA and were able to distinguish the English epidemic MRSA from 
other t y p e s . 吣 _ 6 2 
The major disadvantage of this method is the multiple steps of procedure which is 
technically demanding and increases the possibility for error. Moreover, advanced 
and expensive equipment for DNA electrophoresis and advanced software is 
essential for obtaining good results and meaningful interpretation. Only moderate 
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discriminatory power is found for typing MRSA which exhibit limited genetic 
diversity and a high similarity cut off, such as 94%/' has to be implied. 
1.3.2.2 Analysis of Gene Polymorphism 
Instead of studying the whole bacterial chromosome, genes that are conserved within 
the Staphylococcus species and yet produce acceptable variability between strains 
may be used for typing purpose. Gene encoding the coagulase and protein A, 
namely coa gene and spa gene, have been studied. 
1-3.2.2.1 PCR-Restriction Length Polymorphism (PCR-RFLP) 
Genes related to the epidemicity and virulence of aureus, such as the coa and spa 
genes, are used as epidemiological marker and investigated by the PCR-RFLP 
method. The heterogeneity within the 3’ region of the coa gene have been used for 
typing MRSA.91 PCR is used to amplify this specific fragment and the PGR 
product is digested with a restriction enzyme, Alul. The differences in the number 
and size of fragments contribute to different RFLP patterns. 
PCR-RFLP for the spa gene was also studied based on the X region, a hypervariable 
region, of the spa gene.^ ^ The method is similar to PCR-RFLP for the coa gene but 
Rsal is used instead of Alul. 
The P C R - R F L P method is rapid, easy to perform with good r e p r o d u c i b i l i t y ; 廳 ， 刚 
however, it has lower discriminatory power than and limited patterns 
have been found. Sequence analysis of the spa and coa genes enhances the 
discriminatory power of typing based on gene polymorphisms and is being 
e v a l u a t e d . 3 4 ’ 7 2 ’ n i ’ i 4 o 
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1.3.2.2.2 Random Amplification of Polymorphic DNA (RAPD) 
RAPD uses nonspecific primers and allows random amplification of polymorphic 
DNA occurring at low annealing temperature. ^ ^^  These randomly amplified 
fragments are resolved on an agarose gel and generate DNA fingerprints that 
characterize different bacterial strains and isolates. This method is rapid, easy to 
perform and inexpensive; however, poor reproducibility is observed for the method 
and it is susceptible to technical variation including slight variations in pH or ionic 
strength of the buffers used, the temperature of the reaction, or the source of the 
DNA polymerase. For this reason, comparison between laboratories is also 
problematic. 150 
1.3.2.2.3 Nucleotide Sequence Typing 
1.3.2.2.3.1 A Typing 
The discriminatory power of methods involving single gene polymorphism can be 
increased by sequence analysis of the variable region of these genes. Spa- typing, a 
method which compares the polymorphic region of the spa gene, has been proven to 
be a good typing method with the advantages in terms of rapid in speed, ease of use 
and interpretation, good typability, reproducibility and resolving power, and 
possibility of standardization between laboratories�"’！叫】々？ However, the 
discriminatory power is still lower than PFGE or sequence typing of multiple genes 
(e.g. MLST). 147 
1.3.2.2.3.2 Multilocus Sequence Typing 
Multilocus sequence typing is based on the sequence variation of seven 
housekeeping genes.^^ The sequence of each gene is assigned to an allelic number 
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and the combination of the allelic number of the seven genes contributes to a unique 
profile. This method generates objective, unambiguous and portable data with high 
discrimination and allows standardization between laboratories. A database 
containing the international MLST profile will allow data exchange via internet to be 
a c h i e v e d . 155 Dr. Enright and colleagues have demonstrated that the allelic profile 
generated from this method is compatible with the Sma-l PFGE profile.^^ MLST 
has shown its superiority to PFGE for global epidemiological study.^ '^^ ^ This 
method is labour intensive and time consuming;however , with the new 
development of high throughput sequencing machines, speedy and reliable results 
can be obtained at limited costs. 
1-3.2.3 Hybridization by Southern Blotting 
1.3.2.3.1 M^cA/Tn544 Probe Typing 
This method involves hybridization of Clal digested bacterial DNA using specific 
probes for the mecA gene or Tn554. Fingerprints of the hybridized probe(s) will be 
used for comparison. As all MRSA have the mecA gene and most MRSA have 
Tn544，this method is widely applicable for MRSA s t u d i e s . ^ in addition, the 
staphylococcal mec element has been used as an evolutionary marker for MRSA^o 
and therefore, it has been widely adapted by many research groups.37’39’67’i 丨o 
disadvantage of this method is that multiple steps are required, which is 
time-consuming and labour-intensive and the method is not applicable for clinical 
laboratories for local outbreak studies. 
1.3.2.3.2 Binary Typing 
Binary typing is based on southern hybridization and utilizes probes made by random 
amplification of the staphylococcal g e n o m e . P r o b e s with strain specificity or 
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virulence association can be selected. Each MRSA isolate will be assigned a binary 
code according to the presence or absence of hybridization for each probe. This 
method has good reproducibility, typability and high discriminatory power if large 
numbers of probes are used. Moreover, inter-laboratory comparison is also possible 
due to its standardized reporting format�55，i60 
1.3.2.4 Analysis of Plasmid DNA 
Although >90% of MRSA carry plasmids, it is not a method of choice due to its 
biological characteristics, such as stability of the plasmid and variability of structure 
in related isolates. 
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Table 1.3 Characteristics of strain typing methods for MRSA? 
Typing Typability Reproducibility Discriminatory Ease of Ease of 
System for MRSA Power Interpretation Performance 
Antibiogram All Fair Poor Excellent Excellent 
Phage typing Most Fair Fair Fair Fair 
PFGE All Excellent Excellent Fair Good 
AFLP All Excellent Good Good Fair 
PCR-RFLP All Excellent Good Excellent Excellent 
IIAPD All Fair Good Fair Good 
MecA/Tn544 All Good Good Excellent Good 
Binary typing All Excellent Variable Excellent Good 
Spa-typing All Excellent Good Excellent Good 
MLST All Excellent Excellent Excellent Fair 
Plasmid analysis Most Good Fair Good Excellent 
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1.4 Objectives of the Project 
MRSA is an important nosocomial pathogen in Hong Kong and around the world. 
The objectives of my project are to: 1) develop an effective typing system to 
discriminate between MRSA isolates within PWH to enable selective implementation 
of infection control measures; 2) to determine the relationship between strain 
distribution and MRSA incidence for the period of 1988 to 2000 at the Prince of 
Wales Hospital, Hong Kong. 
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Chapter 2 Materials and Methods 
2.1. Bacterial Isolates & Culture Conditions 
2.1.1. Study Period & Sample Sources 
The bacterial isolates studied were obtained from the MRSA collection saved 
between 1988 and September 2000 at the Prince of Wales Hospital, Hong Kong. 
These samples were stored on nutrient agar slants at room temperature. These 
bacterial strains were isolated from clinical specimens including skin and pus swabs, 
sputum, other respiratory specimen, e.g. tracheal aspirates, body fluids and blood 
cultures. In this study, the isolates were categorized into two groups according to 
their specimen sources: blood cultures (BC) and non-blood cultures (NBC) isolates. 
2.1.2. Selection of Bacterial Isolates 
Between 1988 to 2000，more than 6,000 MRSA isolates were recovered from clinical 
specimens of patients hospitalized at the Prince of Wales Hospital, Hong Kong, of 
which about 800 (13%) from blood. Approximately 10% of these isolates from 
each year were included in the study. Every fourth isolates from the blood culture 
stock and 1 in every 20 consecutive isolates from the non-blood culture collection 
were systematically sampled. All duplicate isolates from the same patient were 
excluded. Any missing, dried or dead cultures were substituted by an isolate with 
the number consecutive to the original chosen isolate. 
2.1.3. Reference Strains 
Twenty-one reference strains were included in this study. They were ATCC 25923 
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aureus), epidemic MRSA 1-16 from the United Kingdom (gifts of Dr. M. Enright, 
Department of Biology and Biochemistry, University of Bath, UK) and 
representatives of the four international MRSA clones, including the Brazilian 
(HSJ216), the Iberian (HPV107), the Pediatric (HDE288) and New York/Tokyo 
clones (BK2464) (gifts of Dr. H. de Lencastre and Dr. A. Tomasz, Laboratory of 
Microbiology, The Rockefeller University, New York, USA). The ATCC strain 
25923 served as an internal standard for each run of tests whilst the other reference 
strains both served as controls (for certain methods) and for comparisons to the Hong 
Kong MRSA isolates. 
2.1.4. Culture & Storage Conditions 
All the bacteria selected were sub-cultured onto blood agar plates and were grown 
overnight at 37°C in aerobic atmosphere. One set of MRSA strains was stored on 
nutrient agar slopes at room temperature and another set in glycerol at -70°C. 
2.1.5. Identification of MRSA 
MRSA strains were confirmed by routine identification methods for S. aureus which 
included a combination of gram stain, colonial morphology, tube coagulase test, and 
thermostable DNAase. Other screening methods, such as Mannitol Oxacillin salt 
agar or Mannitol salt agar, Staph Latex Slide (Serobact, Medvet, Australia), were 
also utilized. Methicillin susceptibility was tested by using a disk diffusion method 
on Mueller-Hinton agar with a 1 昭 oxacillin disk (Oxoid, Basingstoke, UK) that was 
read after 24-48 hours incubation at 30�C. Isolates which gave a reduced zone 
diameter of < 10mm were considered resistant.) 
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2.2. Antibiotic Susceptibility Testing 
A total of 573 MRSA isolates, including 552 MRSA isolates from PWH and 21 
reference strains (ATCC25923, EMRSA 1-16, Brazilian clone (HSJ216), Iberian 
clone (HPV107), Pediatric clone (HDE288) and New York/Tokyo clone (BK2464), 
were tested for antimicrobial susceptibility to thirteen antibiotics by using the disk 
diffusion method.^ The thirteen antimicrobial agents were: tetracycline, mupirocin, 
netilmicin, ciprofloxacin, gentamicin, fusidic acid, tobramycin, co-trimoxazole, 
erythromycin, chloramphenicol, rifampicin, clindamycin and oxacillin (Oxoid, 
Basingstoke, UK). The concentration of the antibiotic agents and the interpretive 
standards are shown in Table 2.1. 
The susceptibility tests were performed following the procedure described by the 
National Committee for Clinical Laboratory Standards (NCCLS).� The MRSA 
isolates were grown for 18 to 20 hours on blood agar plate at 37°C. Isolated 
colonies were used to prepare the cell suspension that was adjusted to 0.5 McFarland 
turbidity standard. Two Mueller-Hinton agar plates were inoculated with the 
inoculum suspension and antimicrobial disks were then dispensed onto the surface of 
the inoculated agar plate. The first six antimicrobial disks listed in Table 2.1 were 
placed on the first plate while the rests, except for oxacillin, were placed on the 
second plate with the clindamycin disks being placed at least 10 mm apart from the 
erythromycin disk. The plates were inverted and incubated at 37�C for 16 to 18 
hours. The plates with the oxacillin disk were incubated at 30�C for 24 hours to 48 
hours. Zones diameters were measured to the nearest whole millimeter. The 
ATCC 25923 was used as control for each run. Any doubtful patterns, such as an 
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isolate showing resistance to an antibiotic that was regularly susceptible in other 
isolates, suspicious of impurity of inoculum or presence of irregular inhibition zone, 
were repeated and confirmed. 
The antibiotic resistance profile of each isolate was entered into the BioNumerics 
database and analyzed by BioNumerics version 2.5 (Applied Math, Belgium). Each 
antibiotic resistance profile included 1 to 12 antibiotics to which the organism was 
resistant. Antibiotics falling into the intermediate susceptibility category were 
considered resistant and were included in the antibiotic resistance profile. The 
isolates were divided into three groups for further study: a) major group: all 
isolates included in this group share one identical antibiotic pattern; b) minor group: 
isolates included in this group have different antibiotic patterns; but at least two 
isolates share one pattern in each subgroup; and c) unique group; isolates in this 
group each has a different antibiotic pattern. Representatives of each group were 
selected for further study. 
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Table 2.1 Zone diameter interpretive standards 
Zone Diameter， 
Antibiotics Disk Content Nearest Whole mm 
Antibiotics (Abbrev.) Antibiotic Concentration R I S 
Oxacillin (Oy 1 |Lig < 10 11-12 > 13 
Tetracycline (T) 1 30 昭 < 14 15-18 > 19 
Mupirocin (M) 2 5 |ig <21 >22 
Netilmicin (N) 1 30 |ig < 12 13-14 > 15 
Ciprofloxacin (Ci) ^ 5 \ig < 15 16-20 > 21 
Gentamicin (G) 1 10 |ig < 12 13-14 > 15 
Fusidic acid (F) 1 lO^ig < 19 20 >21 
Tobramycin (To) ^ 10 jig < 12 13-14 > 15 
Co-trimoxazole (S) ‘ 25 |ag < 10 11-15 > 16 
Erythromycin (E) ‘ 15 |Lig < 13 14-22 > 23 
Chloramphenicol (C) ^ 30 < 12 13-17 > 18 
Rifampicin (R) ^ 5 i^g < 16 17-19 >20 
Clindamycin (D) 1 2 |Lig < 14 15-20 >21 
1 NCCLS 3 
^BSAC standardized disc susceptibility testing method.5 
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2.3. PCR for Mec A Gene 
2.3.1. DNA Preparation and Primer Design for MecA Gene 
The three hundred and twelve MRSA isolates selected for further study were tested 
for the presence of the mecA gene by PCR in order to confirm their resistance to 
methicillin. In order to maintain the stability of the S. aureus DNA for genetic 
comparisons by molecular typing throughout the study and to reduce any likelihood 
of genetic changes which may incur with multiple subcultures, chromosomal DNA 
embedded in agarose plugs were prepared (section 2.4.1.1) and used for both PCR 
and pulsed-field gel electrophoresis. The DNA templates for PCR were prepared by 
cutting a small portion of the DNA plug which was melted in 200 |li1 of distilled 
water at 90°C for 5 minutes. The DNA templates were stored at -20°C. 
A pair of oligonucleotides based on the mecA gene sequence (GenBank accession: 
X52593)i58 were designed and was as follows: 
MecA (F): 5'-TGGCTATCGTGTCACAATCG-3' (1025-1044) 
MecA (R): 5'-CTGGAACTTGTTGAGCAGAG-3' (1309-1328) 
The primer pair amplifies a 304-bp fragment of the mecA gene. This primer pair, 
when aligned with the sequences in the GenBank database, was found to be highly 
specific for the staphylococcal mecA gene and was able to detect all four types of 
SCCwec.67’75 The location of this selected fragment within the four types of 
SCCmec is explained in Table 2.2. 
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Table 2.2 Alignment of amplifled fragment with SCCmec 
SCCmec Type MecA Location Selected Fragment within the MecA Gene 
Type I (AB033763) 31390—33396 32274—32577 (304 bp) (see below) 
Type II (D86934) 4 4 7 7 0 ^ 6 7 7 6 4 5 6 5 4 - ^ 5 9 5 7 (304 bp) 
Type III (AB0376721) 24421—26427 25305—25608 (304 bp) 
Type IVa(AB063172) 17646—19652 18530—18833 (304 bp) 
Type I V b ( A B 0 6 3 1 7 3 ) 13643—15649 14527—14830 (304 bp) 
Type I Amplified fragment 32274 _ _ _ 32577 
MecA gene 31390 33396 
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2.3.2. PCR Amplification for MecK Gene 
2.3.2.1. Master Mix Preparation 
The PCR reactions were performed in 200 |LI1 volume eppendorf tubes by adding 2.5 
|Lil of DNA template to 22.5 |LI1 of master mix containing 10 pmole of each primer, 
0.2mM deoxynucleoside triphosphates mix (Amersham Pharmacia, Biotech, USA), 
0.75 U of Taq DNA polymerase (Amersham Pharmacia Biotech, USA) and 2.5 \i\ of 
lOx PCR buffer (Amersham Pharmacia Biotech, USA). The total reaction volume 
was 25 
2.3.2.2. Polymerase Chain Reaction 
The amplifications were carried out in a GeneAmp PCR System 9700 (Perkin Elmer, 
Applied Biosystem, USA). The reaction began with initial denaturation at 95°C for 
3 minutes, followed by 30 cycles of amplification with denaturation at 94�C for 45 
seconds, annealing at 56°C for 45 seconds, and DNA extension at 72°C for 45 
seconds. The reaction was completed with a final extension at 72°C for 7 minutes. 
2.3.2.3. Analysis of PCR Products by Agarose Gel Electrophoresis 
After amplification, 4 i^l of PCR product and 3 i^l of size marker (50 ng/^il), ^-114 
DNA///ae III Marker (Promega, USA), was loaded onto a 1% (wt/vol) agarose gel 
(Seakem LE agarose, BMA，USA) in 1% TE buffer (Appendix II) for electrophoresis 
and run at 100 V for 1 hour in a electrophoresis gel tank (Amersham Pharmacia 
Biotech, Sweden). The gel was stained with ethidium bromide (l^ig/ml) and 
visualized by a UV transillumination and image system, Thermal Imaging System 
CTI-500 (Perkin Elmer, Applied Biosystem, USA). 
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One positive control, a mecK gene positive MRSA isolate, and one negative control, 
ATCC 25923 (MSSA), were included in each batch of PCR amplifications. 
Internal negative controls containing only the master mix reagent and water instead 
of DNA template were tested in every fifth sample. ATCC 25722 {E. coli) was also 
tested for specificity verification of the primers. 
2.3.2.4. Precautions to Avoid Cross-contamination 
Care was taken to avoid cross-contamination of the PCR samples, in strict adherence 
to the recommendation of Kwok and Higuchi.^ Cultures and DNA extraction were 
performed in a separate area. The PCR master mix and primer aliquots were 
prepared in a 'clean room' separate from where the sample DNA was prepared. 
Amplification and PCR product analyses were also carried out in separate rooms. 
Only a small number of samples were run at any time and a negative control 
containing reaction mixture was run with each batch of PCR. 
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2.4. Pulse-field Gel Electrophoresis (PFGE) 
2.4.1. PFGE Protocol 
The protocol used was based on the Central Public Health Laboratory, Colindale, 
Standard Operating Procedure for PFGE^ with modifications. 
2.4.1.1. DNA Preparation for PFGE 
Bacteria stored in nutrient media were grown on blood agar plates overnight at 37°C. 
A single colony was selected and subcultured onto a fresh blood agar plate, and 
incubated overnight at 37�C. Bacteria colonies were suspended into 500 of SE 
buffer in a 1.5 ml eppendorf tube and the turbidity of the bacterial suspension was 
adjusted to approximately McFarland Standard No.4 (see section 3.4.1. for 
optimization). The cell suspension was mixed with an equal volume of 2% 
low-melting agarose (Sea plaque GTG agarose, FMC BioProducts, USA) (Appendix 
II) to form agarose plug. The plug was then incubated with 1 ml gram-positive 
lysis buffer (Appendix II) containing 30 U/ml lysostaphin (Sigma, USA) and 500 
|ig/ml lysozyme (Sigma, USA) in an eppendorf tube at 37°C in a water bath 
(SHAAKE, USA) overnight. The gram positive lysis buffer was removed and 
replaced with 1ml proteolysis buffer (Appendix II) containing 50 mg/ml proteinase K 
(Amersham Pharmacia Biotech, USA) and incubated at 56�C for 8 hours in a water 
bath (SHAAKE, USA). The plug was then placed into a bijoux and washed with 
TE (Appendix II) buffer (greater than 1ml) at 4°C with constant shaking four times. 
The plugs were kept at 4°C or used for digestion. The buffer was changed every 6 
to 12 weeks. 
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2.4.1.2. Restriction Enzyme Digestion 
A slice of the plug (approx. 1mm) was cut and placed in an eppendorf containing 20 
U of Smal in 100 j^ l restriction enzyme solution (Amersham Pharmacia Biotech, 
Sweden) at 30°C for overnight in water bath (HAAKE, USA). Digested plugs were 
used for electrophoresis or were kept in TE buffer for one week. 
2.4.1.3. Pulse-field Gel Electrophoresis 
The digested plugs were loaded in 1% Seakem Gold agarose gels (FMC BioProducts, 
USA) (Appendix II). Slices of X-DNA markers (Amersham Pharmacia Biotech, 
USA) were placed on the two outside lanes of the gel and after every 8出 or lane 
between samples. The gel was then placed in the gel tank of the Chef Mapper™ 
(BioRad, USA) containing 0.5xTBE buffer (Appendix II). The electrophoresis was 
performed at 6 v/cm and 14�C for 24 hours with pulse times of 5 s to 35 s and a 
linear ramping factor with a 120° angle (see section 3.4.1. for optimization). After 
completion, the gel was stained with ethidium bromide (1 ^ig/ml) for 1 hour and 
de-stained with distilled water for 30 minutes. The separated fragments were 
visualized by a UV transillumination and image system, Thermal Imaging System 
CTI-500 (Perkin Elmer, Applied Biosystem, USA). The gel images were stored in 
Tagged Image File Format (Tiff) for analysis. 
2.4.1.4. Standards & Markers for PFGE 
ATCC 25923 and one MRSA isolate (#3) were included in each agarose gel for 
PFGE controls and for comparisons between gels. >,-DNA PFGE marker 
(Amersham Pharmacia Biotech, USA) was run every 8出 or lane in each PFGE gel 
for inter- and intra-gel alignment. 
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2.4.2. Optimization of PFGE 
The procedure was optimized to obtain the best image of the gel in terms of good 
resolution with clear separation of bands. The following conditions were 
optimized: 1) turbidity of cell suspension during plug preparation; 2) pulsing 
protocol: multi-state vs. two-state; and 3) duration of electrophoresis. 
Cell suspensions of different turbidity to McFarland Standard 2, 3, 4, 5 and >5 were 
prepared and agarose plugs were made. 
Three sets of plugs were prepared according to the methodology described in section 
2.4.1 and were loaded into three different gels. The electrophoresis of the first gel 
was run by using multi-state pulsing protocol: 5 s to 15 s in the first 10 hours 
followed by a further 10 hours using a pulse time of 15 s to 45 s. The gel was 
run for 24 hours with pulse times of 5 s to 35 s. The 3rd was run for 30 hours 
with the pulse time remaining identical to the 2"'' gel. 
2.4.3. Computer Analysis of PFGE Pattern 
The gel images were edited and analyzed by BioNumerics version 2.5 (Applied 
Maths，Belgium). After normalization and background subtraction, bands were 
assigned automatically by using band search filter settings at a minimal profiling of 
50/0, a minimal area of 0.5% and shoulder sensitivity of 5. Manual adjustment was 
required to correct the mis-assigned bands. The comparative analysis of PFGE 
patterns was preformed with the Dice band-based similarity coefficient and by using 
optimization and band tolerance of 1%. The, dendrogram was generated by 
unweighted pair-group method by using average linkages (UPGMA). The PFGE 
patterns were also interpreted visually based on Tenover's criteria'^^ with slight 
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modification. The classification of PFGE types for this project was defined as 
follows: 1) pulsotype type Ala was the major type, if there were more than 3 band 
differences from this typical pattern (type A pattern), it would be defined as a new 
major type; 2) if there were equal or less than 3 band differences, it would be defined 
as a subtype of a major type, indicating as; 3) if the number of band differences was 
the same but at a different position, it would be described as a sub-subtype of the 
major type (Table 2.3). 
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Table 2.3 Interpretation of PFGE types 
Category Type No. of fragment different  
from major type 
Main Type A，B，C... > 3 bands 
Subtype 1,2,3.. . ^ 3 bands 
Sub-sub type a, b，c... same no. of bands，but 
band difference at different position 
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2.5. Amplified Fragment Length Polymorphism 
2.5.1. Amplified Fragment Length Polymorphism (AFLP) Protocol 
The AFLP was performed according to protocol obtained from the Central Public 
Health Laboratory, Colindale.^^ The procedure was carried out in four stages: 1) 
DNA preparation, 2) enzyme digestion and ligation, 3) PCR amplification, and 4) gel 
electrophoresis. 
2.5.1.1. DNA Preparation 
Bacteria were grown overnight on blood agar plates at 37°C aerobically. Genomic 
DNA was isolated from plate culture by using Wizard Genomic DNA Purification 
Kit (Blood Sample) (Promega, USA) according to the manufacturer's instruction. 
Briefly, one loopful of colonies was washed with 1 ml EDTA buffer (50mM; pH 8) in 
an eppendorf tube and digested with 600 |il of EDTA buffer containing lysozyme 
(500 ^ig/ml) and lysostaphin (200 U/ml) for 1 hour at 37�C. The cell suspension 
was mixed with 600 |il of Nucleic Lysis solution and heated at 80�C in water bath for 
5 minutes. The suspension was treated with 3 |il of RNase for 30 minutes at 37�C. 
Protein was precipitated out by adding 200 |il of Protein precipitation solution on ice 
for 10 minutes. After centrifugation at 13,000 rpm for 10 minute using a 
microcentrifuge (Micro Centrau, Sanyon, UK), supernatant was obtained and DNA 
was then precipitated by 600 |j,l of isopropanol. DNA was washed twice with 95% 
ethanol, each time centrifuged at 13,000 rpm for 1 minute to retain the pellet. The 
pellet of DNA was dissolved by DNA rehydration solution in the final volume of 
100|il. The concentration of DNA was estimated by UV spectrophotometry at A260 
(Lambda Bio 40，Perkin Elmer, USA). The ratio of absorption at 260 nm over that 
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at 280 rnn was also calculated for DNA purity evaluation. The final DNA 
concentration was adjusted to 1 O.D. (50 ng/jil) for all isolates and stored at 4°C 
until use. 
2.5.1.2. Enzyme Digestion & Ligation 
The enzymes Msel and EcoRl were used to digest DNA as follows: DNA template 
(approx. 500ng) was incubated with Msel (5 U/|il) (NewEngland BioLabs, USA), Ix 
Msel reaction buffer (NewEngland BioLabs, USA), Ix BSA (NewEngland BioLabs, 
USA) and RNase (lOmg/ml) (Amersham Pharmacia, Biotech, USA) in a final 
volume of 20 at 37°C for 1 hour and followed by another 1.5 hour incubation at 
the same temperature with the addition of EcoRl (5 U/|il) (Gibcobrl, Life 
Technologies, USA) and Ix EcoRl buffer (Gibcobrl, Life Technologies, USA) to the 
reaction mixture and in a final volume of 25 i^l. The mixture was incubated at 65°C 
for 10 minutes (PTC-200 DNA engine, MJ Research, USA) to inactivate the enzyme 
activities. Ligation of the double-digested DNA was performed by adding 五c(?RJ 
adaptor (1 |aM), Msel (10 |LIM) adaptor (Life Technology, USA) (Table 2.5-1), T4 
DNA-ligase (2 U/^il) (Amersham Pharmacia, Biotech, USA) and Ix reaction buffer 
to the digested DNA in a final volume of 50 at 16�C for 16 hours (PTC-200 DNA 
engine, MJ Research, USA). The sample was stored at -20°C or used immediately 
for PCR. 
2.5.1.3. PCR for AFLP 
PCR was performed in 25卞 1 volume containing 2.5 |al ofligated DNA and 22.5 |LI1 of 
PCR master mix containing 2 i^M of Cy-5-labeled EcoRl primer (Genset，SA) and 5 
I^M of Msel primer containing the extra selective base C (Msel+C) (Life Technology, 
USA), 0.2 mM dNTP (Amersham Pharmacia, Biotech), 0.75U of Tag polymerase 
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and 2.5 jxl of lOx PCR buffer (Amersham Pharmacia, Biotech). The touchdown 
PCR reaction was performed in a DNA thermal cycler (GeneAmp PCR system 9600， 
Perkin Elmer, USA) and the conditions as according to Grady et.al.64 The reaction 
profile was as follow: 1 cycle of 20 s at 94°C, 30 s at 66°C, and 2 min at 72°C; 9 
cycles of 20 s at 94°C, 30 s at an annealing temperature 1°C lower than that of the 
previous cycle (starting at 65°C), and 2 min at 72°C; and 20 cycles of 20 s at 94°C, 
30 s at 56°C, and 2 min at 72°C. PCR product (5 |il) was mixed with 3 of 
loading dye (formamide and bromphenol blue dye) and was denatured at 94°C for 3 
minutes in a DNA thermal cycler (GeneAmp PCR system 9600，Perkin Elmer, USA). 
Two Cy-5-labeled size markers, one ALFexpress size marker (50-500 bp) 
(Amersham Pharmacia Biotech, USA), and an additional marker of a 75 bp 
oligonucleotide (Genset，USA) (see section 2.5.1.5 for description), were also 
prepared: Ip,! of ALFexpress size marker (5 fmole/^il) was mixed with 1 \xl of 75 bp 
oligonucleotide (25 ftnole/|xl), 3 of loading dye (Amersham Pharmacia Biotech, 
USA) and 3 \i\ of TE buffer. The mixture of size markers was also denatured in the 
same way as other samples. 
2.5.1.4. Gel Electrophoresis for AFLP 
The separation of the amplified fragments was done through a 6% polyacrylamide 
plus 7 M urea denaturing gel (Amresco, USA) in O.SxTBE buffer on an ALFexpress 
DNA sequencer (Amersham Pharmacia Biotech, USA). The electrophoresis was 
performed at 1,500 V，60 mA, and 25 W for 700 min at The ALFexpress 
captured data at every 2 s and these raw data were stored in ALX format which had 
to be converted to TIFF format for further analysis. 
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2.5.1.5. Standards & Markers for AFLP 
Control strains, namely ATCC 25923, one MRSA isolate (#34) and EMRSA-15, 
were included in each gel for inter- and intra-gel comparison. ATCC 25923 and 
MRSA isolate (#34) were processed with each batch of samples for reproducibility. 
If discrepancy occurred, all the samples in the whole gel would be repeated. 
The Cy-5-labeled markers used in this method were prepared from mixing the 
ALFexpress sizer 50-500 (5 fmole/|il) (Amersham Pharmacia Biotech, USA) with an 
additional 75 bp oligonucleotides (25 fmole/jxl) (Genset, SA). The ALFexpress 
sizer 50-500 is a 50 bp step-ladder size marker. However, most of the AFLP 
fragments generated from S. aureus were found between size 50-150 bp. Therefore, 
additional size markers with size between 50-150, e.g. 75 bp, 125 bp, were useful in 
adding standard points for gel alignment. Improvement in gel alignment increases 
reproducibility of the method by minimizing the variation during electrophoresis. 
Two extra markers (75 bp and 125 bp) were initially designed to be synthesized; 
however, the oligonucleotide of 125 bp was too large to be synthesized in good 
quality to produce a sharp band, hence only the 75 bp oligonucleotide was made 
eventually as an additional size marker. 
The Cy-5-labeled markers were included in each gel and were run every 4 or 5 lanes 
as reference points for inter- and intra- gel alignment. 
2.5.2. Computer Analysis for AFLP Patterns 
The raw data collected from ALFexpress in ALX format at 0 s to 7000 s for the 
duration of gel electrophoresis were selected and converted to TIFF format with a 
resampling value of 3，gutter value of 2 and lane width of 25. The data were 
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converted to TIFF format in order to be imported into computer software, 
BioNumerics version 2.5 (Applied Maths, Belgium), for data analysis. After 
normalization and background subtraction, bands were assigned automatically by the 
band searching function setting at a minimal profiling of 1% and minimal area of 
0.15%. Manual adjustment was also required for correcting any mis-identified 
bands. Cluster analysis of the AFLP patterns was performed with the Dice 
similarity coefficient by using optimization at 0.1%, position tolerance and change 
toward end of fingerprint at 0.3%. Dendrograms were calculated by the unweighted 
pair-group method by using average linkages (UPGMA). 
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Table 2.4 Adaptors and primers for AFLP 
Adaptors 1 EcoRI adaptor (double stranded) 
5 丨-CTCGTAGACTGCGTACC-3 ’ 
3'-CATCTGACGCATGGTTAA-5' 
Msel adaptor (double stranded) 
5 丨-TACTCAGGACTCATC-3’ 
3，-GAGTCCTGAGTAGCAG-5’ 




1 The EcoRl and Msel adaptors were designed according to the protocol and were 
prepared as follows: equimolar amounts of two complementary oligonucleotide 
sequences (五coRI: 5'-CTCGTAGACTGCGTACC-3' and 
3 '-CATCTGACGCATGGTTAA-5') (Msel: 5'-TACTCAGGACTCATC-3 ’ and 
3'-GAGTCCTGAGTAGCAG-5') were mixed together and heated to 95°C for 10 
minutes and slowly cooled to room temperature. 
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2.6. Phage Typing 
2.6.1 • Phages & Propagating Strains 
A set of international phages including twenty-three phages in liquid suspensions at 
RTD lOOOx were issued from the Central Public Health Laboratory, Colindale, UK. 
Twenty-two propagating strains in freeze-dried ampoules were also obtained (gift of 
Dr. Tyrone Pitt, CPHLS, Colindale, UK). The phage suspensions were diluted to 
RTD lOOx as a working solution. The propagating strains were reconstituted and 
kept in nutrient agar slope at room temperature and stored in the dark. The list of 
propagating strains for each phage is shown in Table 2.5. 
2.6.2. Phage Typing Protocol 
The protocol used was based on the Central Public Health Laboratory, Colindale, 
Standard Operating Procedure for phage typing丨 and according to recommendation 
by Aucken et. al.'^ to phage type MRSA with lOOx RTD or lOOOx RTD. Isolated 
bacterial colonies were inoculated into 3 ml BHI broth and incubated at 37°C in air 
for 16 hours. The grown culture was then flooded onto a soft nutrient agar plate 
containing calcium chloride (SCC plate; Appendix II). The plates were air dried at 
room temperature for approximately two hours and 5 of each phage from the basic 
international set'^^ were applied at lOOx RTD with an automatic pipette. The 
inoculated plate was allowed to dry and incubated at 30�C aerobically overnight. 
The plate was read visually on the next day and the reactions were graded as negative; 
inhibition; weak lytic reaction and strong lytic reaction (Table 2.6). Any strains 
nontypable by lOOx RTD were tested with lOOOx RTD. 
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Table 2.5 Phages and propagating strains 
Phage No. Propagating Strain 
29 NCTC 8331 
52 NCTC 8507 
52A NCTC 8363 
79 NCTC 8363 
80 NCTC 9789 
3A NCTC 8319 
3C NCTC 8327 
55 NCTC 8358 
71 NCTC 9315 
95 NCTC 10971 
6 NCTC 8509 
42E NCTC 8357 
47 NCTC 8325 
53 NCTC 8511 
54 NCTC 8329 
75 NCTC8354/EMRSA121 
77 NCTC 8356 
83A NCTC 10039 
84 NCTC 10455 
85 NCTC 10457 
81 NCTC 9717 
94 NCTC 10970 
96 NCTC 10972 
I n C T C 8354 was dead during shipping and EMRSA 12 which was expected to give 
confluent lysis reaction for phage 75 was used for substitution. 
、 
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Table 2.6 Reaction grading and interpretation of phage typing. 
No. of plaques Grading at 100 or lOOOx RTD Interpretation 
1-5 plaques 1 Weak reaction 
6-19 plaques 2 Weak reaction 
20-49 plaques 3 Weak reaction 
^ 50 plaques 8 Strong reaction 
Confluent lysis 9 Strong reaction 
Inhibition reaction 0 Variable! 
1 Sometimes inhibition reaction and a strong reaction with > 50 plaques are 
interchangeable. Consistency in grading should be followed. 
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Figure 2.1 Different grading of phage reactions 
Weak reactions: 1 (1-5 plaques), 2(5-10 plaques) 
Strong reactions: 8 (>50 plaques), 9 (confluent lysis) 
Inhibition reaction: 0 (inhibition of growth) 
Reactions shown in red arrows could be interpreted as strong lytic 
reaction or inhibition. Consistency in interpretation was maintained 
and read as inhibition. 
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The phage lysate was checked once weekly by adding one drop (20 of the phage 
suspension to the plate inoculated with the appropriate propagating strain. Strong 
lytic reaction (more than 50 plaques) should be observed and any phage dilution with 
weak lytic strength was discarded. The working dilution for the phages was kept at 
4°C for two weeks and discarded. 
EMRSA 16 and one MRSA isolate (#22) were phage typed with other isolates in 
each batch of tests for control of the test conditions. These two MRSA strains were 
selected as controls due to their reactivity to a number of different phages. 
In order to evaluate the reproducibility of the phage typing result, four MRSA 
isolates，EMRSA 3，EMRSA 16，MRSA (#20) and MRSA (#22), were phage typed 
under different conditions as follows: 
1. Duplicate cell suspensions of each isolate was made and inoculated onto two 
different plates; 
2. One cell suspension of each isolate was made and inoculated onto two different 
plates; 
3. Cell suspensions of each isolate were prepared on different days and inoculated 
onto two different plates. 
2.6.3. Data Analysis and Result Interpretation for Phage Typing 
The results were entered into the BioNumerics database and analyzed by 
BioNumerics version 2.5 (Applied Maths, Belgium). The analysis of strain types 
was done by following the three-reaction-difference mle.'^ 
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2.7. Other Typing Methods 
2.7.1. PCR Restriction Fragment Length Polymorphism for the 
Coa Gene 
2.7.1.1. Primer Design 
A pair of oligonucleotide primers was designed based on three coagulase gene 
sequences for aureus (Gene Bank accession no.: D00184,^^ X16457^®) 
which would amplify an approximate 500-bp fragment of the coa gene. The 
primers were: 
Coal(F) 5'-TATAGAGATGCTGGTACAGG-3' (1512-1531 from X16457) 
Coa2 (R) 5,-CTGTATGTCTWTGGATAGAG-3, (2081-2100 from 7x16457) 
A "W" was used in the reverse primer in order to allow the variation between "A" 
and "T" base at that position (W stands for A/T variation). 
2.7.1.2. DNA Preparation 
DNA template was prepared following the procedure described in section 2.3.1. 
2.7.1.3. Optimization of PCR 
The optimal DNA template concentrations, primer concentration and DNA 
polymerase, polymerization mix were determined by titration. Two brands of DNA 
polymerase were also evaluated for production of strong PCR products. The 
annealing temperature for PCR was also optimized to obtain a single strong band of 
the appropriate size. These optimized conditions (Figure 3.18) were used 
subsequently. 
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After final optimization, the master mix containing 0.4 FIM of each primer, 150 |LIM 
of dNTP, 5 i^ il of lOx PCR buffer and 1.5 U of Taq DNA polymerase (Amersham 
Pharmacia Biotech, USA) was mixed with 5 |il DNA template in a total volume of 50 
|j,l reaction solution. 
2.7.1.3.1. PCR Amplification 
The amplifications were carried out in a GeneAmp PCR System 9600 (Perkin Elmer, 
Applied Biosystem, USA). The reaction began with an initial denaturation at 95°C 
for 5 minutes. Thirty cycles of amplification were performed as follows: 
denaturation at 94°C for 45 seconds, annealing at 50°C for 45 seconds, and DNA 
extension at 72°C for 45 seconds. The reaction was completed with a final 
extension at 72°C for 7 minutes. Gel electrophoresis of the PCR product was 
performed according the procedure described in section 2.3.2.3. 
2.7.1.3.2. Restriction Enzyme Digestion 
Restriction enzyme digestion was done by incubating the mixture of 5 |il of PCR 
product with 0.2 of AM (1 unit), 1 |il of lOx buffer and 4 \i\ of distilled water in a 
total volume of 10 |il at 37°C overnight. The digested PCR product was loaded into 
2% Metaphor agarose gel (BMA, USA) and electrophoresis performed at 60 V/cm 
for 2 hours. A Lambda DNA-Hind III/ (|)-174 DNA-Z/oe III Digest size marker 
(Amersham Pharmacia, Biotech, USA) was used. 
2.7.2. Multi-locus Sequence Typing 
This method was performed according to the MLST protocol used at the University 
of Bath provided by Dr. M. Enright (Department of Biology and Biochemistry, 
University of Bath, UK). The procedure was carried out in the lab of Dr. M. 
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Enright (Department of Biology and Biochemistry, University of Bath, UK). 
2.7.2.1. Preparation of Chromosomal DNA 
The bacterial isolates were grown overnight on blood agar plates at 37°C overnight 
in 5% CO2. Cell suspension was made by resuspending 1/8 of a plate of overnight 
confluent growth from a blood agar plate in 400 \i\ of lysis solution containing 
lysozyme (2500 U/ml) and lysostaphin (250 U/ml) at 37°C for over 30 minutes until 
completely lyzed. The cell solution was heated at 95°C for 10 minutes in heat 
block and then cooled on ice and mixed with 1 ml phenol/chloroform isoamyl 
alcohol (25:24:1). The suspension was centrifuged at 10,000 g for 20 minutes in a 
micro centrifuge. The aqueous layer containing DNA was transferred to a fresh 
eppendorf tube and DNA was precipitated with 1 ml absolute ethanol and allowed to 
cool on ice for 15 minutes. The eppendorf tube was centrifuged at 10,000 g for 20 
minutes and the supernatant was discarded. The DNA pellet was resuspended in 50 
of TE buffer. 
2.7.2.2. PCR for MLST Gene 
Primers for the seven house keeping genes were obtained from the MLST web site 
(http://www.mlst.net/) and are listed in Table 2.7. 
The 50-|al volume reaction contained 1 |il of forward and reverse primers (100 
pmol尔 1)，5 1^1 of lOx Qiagen buffer, 1 pi of dNTPs (10 mM), 0.5 \x\ of Tag 
polymerase (Qiagen, Crawley, UK), 39.5 fil of distilled water and 2 fil of DNA 
template. 
The amplification was performed in a PTC-200 DNA engine (MJ Research, Boston, 
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Table 2.7 PCR/Sequencing primers for MLST (http://www.mlst.iiet/) 
Gene Primers  
arc (Carbamate kinase) 5' TTG ATT C A C C A G C G C G T A TTG TC -3' 
5' A G G TAT C T G CTT C A A TCA G C G -3' 
aro (Shikimate dehydrogenase) 5' ATC G G A A A T CCT ATT TCA C A T TC -3, 
5' G G T GTT G T A TTA A T A A C G A T A TC -3' 
glp (Glycerol kinase) 5' CTA G G A A C T G C A ATC TTA ATC C -3' 
5' T G G T A A A A T C G C ATG TCC A A T TC -3' 
gmk (Guanylate kinase) 5' ATC GTT TTA TCG G G A C C A TC -3’ 
5' TCA TTA A C T A C A A C G T A A TCG TA -3' 
pta (Phosphate acetyltransferase) 5' GTT A A A A T C G T A TTA CCT G A A G G -3' 
5' G A C CCT TTT GTT G A A A A G CTT A A -3' 
tpi (Triosephosphate isomerase) 5, TCG TTC ATT CTG A A C GTC G T G A A -3’ 
5' TTT G C A CCT TCT A A C A A T TGT A C -3' 
yqi (Acetyle coenzyme A acetyltransferase) 5' C A G CAT A C A G G A C A C CTA TTG G C -3' 
5’ CG T T G A G G A ATC GAT A C T G G A A C -3’ 
66 
Chapter 2 Materials and Methods 
Mass. USA) with denaturation at 95°C for 3 minutes followed by 34 cycles of 
denaturation at 95°C for 30 seconds, annealing at 55°C (50�C was used for arc gene) 
for 30 seconds and extension at 72�C for 1 minute. The final extension was at 72�C 
for 10 minutes. The presence of PCR product of the approximate size was 
confirmed by gel electrophoresis. 
2.7.2.3. Purification of DNA for Sequencing 
The PCR product was mixed with 60 i^l of 20% PEG/2.5M NaCl and incubated at 
room temperature for 30 minutes or at 4°C overnight. 
The PCR product mixed with PEG/NaCl was centrifuged at 3000-3200 rpm at 4°C 
for 1 hour and the supernatant was removed. The remaining PEG/NaCl was 
removed by centrifuging at 500 rpm for 20 seconds and discarding the supernatant. 
The DNA pellet was washed by mixing with 150 i^l of 70% ethanol. After 
centrifuging at 3000-3200 rpm for 15-20 minutes, the supernatant was removed. 
This step was repeated once for removing leftover ethanol. The DNA pellets were 
dried at 37�C for 2 minutes and resuspended in 10 i^l of distilled water and was kept 
at -20°C before use. 
The sequencing reaction was set up as follows: 1 |LI1 of purified PCR product was 
added to 0.5 |li1 of forward or reverse primers (1 pmol/|al) and 1 of Taq FS 
(BigDye) (Applied Biosystems, USA). 
2.7.2.4. PCR for Sequencing 
The PCR was performed in a PTC-200 DNA engine (MJ Research, Boston, Mass. 
USA) using the following conditions: 96�C for 10 seconds, 50°C for 5 seconds, 
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60°C for 2 minutes. This cycle was repeated for 24 times and then cooled down to 
4°C. 
The sequencing product was precipitated by mixing with 50 i^l of 95% ethanol and 2 
1^1 of sodium acetate and incubated at -20°C for 1 hour. 
The above solution was centrifuged at 3500 rpm at 4°C for 1 hour and supernatant 
was discarded. The supernatant was further removed by a second centrifugation at 
500 rpm for 1 minute. Then, the DNA pellet was washed with 150 of 70% 
ethanol, centrifuged, and the supernatant removed, and the DNA was stored at -20°C 
until ready for loading to the ABI 3700 sequencer (Applied Biosystems, USA). 
2.7.2.5. Sequencing by Automatic DNA Analyzer & Data Analysis 
A micro-titer plate with 96 reaction wells that contained 96 different sequencing 
reactions was placed on the ABI 3700 DNA analyzer (Applied Biosystems, USA) for 
electrophoresis by capillary method. For each locus, the sequences of all isolates 
were compared with the existing sequences obtained from the MLST website 
(http://www.mlst.net/). Any different sequence would be assigned a new allelic 
number. For each isolate, the alleles at each of the seven loci defined the allelic 
profile that correspond to the sequence type (ST). Cluster analysis was done by 
BURST, an algorithm used to discern groups of isolates among large MLST datasets. 
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Chapter 3 Results 
3.1. Bacterial Isolates 
A total of 941 MRSA isolates were sub-cultured from the MRSA collection saved at 
PWH to confirm their identities and the methicillin resistance. However, due to the 
loss of viability of the bacteria and spontaneous loss of the methicillin gene during 
storage69 only 552 isolates were successfully recovered with confirmed identification. 
Among these isolates, 439 were non-blood culture and 113 were from blood culture. 
Any duplicate isolate from the same patient was excluded from the study. A mean 
of 11% of all MRSA isolates was examined in this project. Limited number of 
isolates were studied before 1993 because of the incomplete storage of the isolates. 
The number of isolates studied in each year is listed in Table 3.1 and the total number 
of MRSA isolated at PWH in each year is shown in Figure 3.1. 
All the reference strains obtained from abroad were confirmed to be MRSA isolates. 
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Table 3.1 Number of MRSA isolates selected for this study between 1988-2000. 
Total no. ofl � • � , NBC (Selected for BC (Selected for 
v iv/D�A4 MRSA Selected for Total no. Total no. . . , ^ , Year IVRS^at study) (% study) 
PWH oftot^NBC) (%oftotal BC) 
1988^ Unknovvn 9 9 0 
1989^ 557 9 509 48 9 2% 0 
1990 528 15 2.8% 490 38 14 3% 1 3% 
1991 368 21 5.7% 326 42 17 5% 4 10% 
1992 390 21 5.4% 339 51 15 4% 6 12% 
1993 412 31 7.5% 372 40 28 8% 3 8% 
1994 408 36 8.8% 362 46 32 9% 4 9% 
1995 443 58 13.1% 349 94 44 13% 14 15% 
1996 554 56 10.1% 458 96 43 9% 13 14% 
1997 592 57 9.6% 486 106 32 7% 25 24% 
1998 725 80 11.0% 601 124 65 11% 15 12% 
1999 682 78 11.4% 560 122 65 12% 13 11% 
2000^ 558 81 14.50/0 m ^5 
Total no. 6217 552 439 一 “ T \ Z 
^MRSA isolates collected between Jan—Oct'00 were included and the total number 
of MRSA isolates from NBC and BC were not calculated. 
^MRSA isolates from blood culture isolated between 1988 and 1989 could not be 
found from the MRSA stock. 
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No. of MRSA at PWH (1989-1999) 
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Figure 3.1. Total number of MRSA isolated at PWH (1989—1999) 
A steady increase of MRSA isolates at PWH was found from 1991 一1998. 
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3.2. Antibiotic Susceptibility Testing 
The percentage of antibiotic resistance is shown in Table 3.2. The majority of 
MRSA strains analyzed were resistant to tetracycline (96.9%), erythromycin (99.6%), 
clindamycin (76.6%), gentamicin (94.9%), tobramycin (94.2%), and ciprofloxacin 
(89.50/0). Resistance to the rest of the antibiotics is low (5-17%) and none of the 
isolates showed resistance to all tested antibiotics. The antimicrobial resistance 
patterns of 552 MRSA isolates are listed in Table 3.3. A total of 80 different MRSA 
resistance patterns were obtained among 552 isolates from the period 1988—2000. 
The predominant antibiotic resistance profile is pattern I (TeEDGToCi), which is 
expressed by 46% (255/552) of MRSA isolates and was present from 1990—2000. 
Fifteen other patterns, each made up of 2 or more isolates, made up 42% (233/552) 
of all the isolates. The remainder 12% (64/552) isolates had unique antibiotic 
resistance patterns. 
The distribution of MRSA isolates with the major susceptibility patterns over the 
13-year period is shown in Figure 3.2. Six patterns were designated major patterns 
( � 1 0 isolates each) and these included 68% (378/552) of all isolates. The 
distribution of the patterns indicates strongly that a predominant clone, with 
antibiotic resistance pattern I, TEDGToCi, was present throughout 1990-2000. 
Prior to 1990，all the isolates tested were susceptible to ciprofloxacin and that the 
MRSA isolates had diverse antibiotic resistance patterns. In early and mid-1990s, 
two or more dominant strains were present each year and emergence of new 
antibiotic resistances, such as co-trimoxazole (1990)，rifampicin (1991), netilmicin 
(1992), fusidic acid (1994)，mupirocin with netilmicin (1995), was also found during 
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Table 3.2 Resistant percentage to antibiotic agents. 
Antibiotic No. of Isolates Resistant (N=552) (%) 
Erythromycin 550 (99.6%) 
Tetracycline 535 (96.9%) 
Gentamicin 524 (94.9%) 
Tobramycin 520 (94.2%) 
Ciprofloxacin 494 (89.5%) 
Clindamycin 423 (76.6%) 
Netilmicin 93 (16.8%) 
Mupirocin 80 (14.5%) 
Fusidic acid 36 (6.5%) 
Rifampicin 35 (6.3%) 
Co-trimoxazole 34 (6.2%) 
Chloramphenicol 28 (5.1 %) 
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Table 3.3 Antibiotic Resistance Profiles of 552 MRSA isolates from PWH 
(1988—2000) 
Pattern l^pe Antibiotic Resistance Pattern* No. of Isolates, N=552 (%) 
I TEDGToCi 255 (46%) 
II TEGToCiNM 37 (6.7%) 
III TEGToCi 34 (6.2%) 
IV TEDGToCiN 24 (4.3%) 
V TEDGToCiM 15 (2.7%) 
VI TEDGTo 13 (2.4%) 
VII TEDCi 10 (1.8%) 
VIII TEDGToCiR 10 (1.8%) 
IX TEGToCiM 9(1.6%) 
X TEDGToCiS 8 (1.4%) 
XI TEDGToCiNM 8 (1.4%) 
XII TEDGToS 6(1.1%) 
XIII EDGToCiR 6(1.1%) 
XIV TEDGToCiF 6(1.1%) 
XV TEDGToC 5 (0.9%) 
XVI TEGToCiF 5 (0.9%) 
U# Unique pattern (single isolates) 64 (11.6%) 
* Antibiotic resistance is denoted by E (erythromycin), T (tetracycline), G 
(gentamicin), To (tobramycin), Ci (ciprofloxacin), D (clindamycin), N (netilmicin), 
M (mupirocin), F (fusidic acid), R (rifampicin), S (co-trimoxazole) and C 
(chloramphenicol). 
M  
See Appendix IV for details. 
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this period. By late 1990s, the MRSA isolates belonging to pattern I became 
established in the hospital to be the predominant clone. 
According to the antibiotic susceptibility patterns, the isolates were categorized into 
three groups (Table 3.4): group A, major group, isolates showed identical antibiotic 
resistance pattern; group B, minor group, two or more isolates which shared the 
antibiotic resistance pattern different from the pattern of group A and group C, 
unique group with single isolates of unique antibiotic resistance pattern. 
Representatives from each antibiotic group selected for PFGE typing are listed. 
(Table 3.4) 
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Table 3.4 Definition of antibiotic groups and isolates selected for further 
studies. 
Isolates 
Antibiotic No. of Isolates No. of Pattern Total no. of selected for 
Group (same pattern) Isolates PFGE 
Major Group NA 1 255 74 
Minor Group ^ 2 15 233 174 
Unique Group 1 64 64 64 
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Figure 3.2. The antibiotic resistance patterns are I, TEDGToCi; II, TEGToCiNM; 
HI, TEGToCi; IV，TEDGToCiN; V, TEDGToCiM; VI, TEDGTo, and Uniq, single 
isolates of unique pattern. Antibiotic resistance is denoted by tetracycline T, 
erythromycin E, clindamycin D, gentamicin Q tobramycin To, ciprofloxacin Ci, 
netilmicin N, mupirocin M. 
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3.3. PCR for MecA Gene 
All 312 MRSA isolates typed by PFGE and examined for the presence of mecA gene 
were confirmed to be positive by PCR. The primer pairs produced amplified 
product of about 310bp, as shown in Figure 3.3. However, a small number of 
isolates gave no or weak positive signals using DNA prepared from PFGE plugs, 
DNA extraction was repeated by using the DNA extraction kit method described in 
section 2.5.1.1. After repeating the extraction and the PCR, only 7 isolates (2.2% of 
all samples tested) remained as weak positive. 
The specificity of the primer pairs was tested. All the MRSA reference strains 
produced strong positive PCR but the negative strains, ATCC 23923 (MSSA) and 
ATCC 25722 (E.coli), remained negative by PCR throughout (Figure 3.3). 
78 
Chapter 3 Results 





Figure 3.3. PCR for mecA gene. Lane 1，(|)-174 D^A/Hae III Marker; lane 2, 
Brazilian clone; lane 3，Iberian clone; lane 4 N.Y./Tokyo clone; lane 5, Pediatric 
clone; lane 6，EMRSA 16; lane 7 MRSA (PWH; 99/1602); lane 8，ATCC 25923 
(MSSA); lane 9，ATCC 25722 (E.coli); lane 10, reagent control. 
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3.4. Pulsed-field Gel Electrophoresis 
3.4.1. Optimization of PFGE 
Figure 3.4 shows the PFGE image prepared from different turbidities of cell 
suspensions. Cell suspensions of three different isolates were prepared at five 
different turbidities, namely McFarland 2，3，4, 5，>5，for the preparation of agarose 
plugs for PFGE. Fragments generated from the plugs with cell suspension greater 
than McFarland 5 were too thick and it was difficult to distinguish single or multiple 
bands whilst fragments generated from the plugs with cell suspensions equal to 
McFarland 3 or 2 were too weak and the resolution of the smaller sized fragments 
was poor. The cell suspension with McFarland 4 was chosen as it gave sharp and 
distinct bands which were easily interpretable and clearly separated visually. 
Figure 3.5a-c shows three PFGE gel images with three different pulsing protocols: a) 
10 hours with 5-15 s ramping time, followed by 10 hours with 15-45 s ramping time; 
b) 24 hours with 5-35 s ramping time; c) 30 hours with 5-35 s ramping time (see 
section 2.4.2. for details). The electrophoresis using pulsing protocols for Figure 
3.5a and Figure 3.5b produced good resolution of image and clear separation of 
bands whilst increasing the run time to 30 hours decreased the resolution 
dramatically (Figure 3.5c). Gel electrophoresis using the multi-state pulsing 
protocol generated the "smiley effect" of lanes and was unsatisfactory for inter-gel 
comparison. As a result, the pulsing protocol using 24 hours with 5-35 s ramping 
time was chosen for it gave relatively good resolution, band separation and 
reproducibility on repeated gels. 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
_ 
Figure 3.4. Turbidities of cell suspension for PFGE agarose plugs. 
Lanes 1，7,13 and 19: X-D^A PFGE markers. PFGE profiles of three MRSA 
isolates after digestion by Smal were represented on lanes 2-6，lanes 8-12, and lanes 
14-18，respectively. Lanes 2，8 and 14: PFGE profiles of MRSA from agarose 
plugs prepared from cell suspension of McF>5; lanes 3, 9 and 15: prepared from cell 
suspension of McF 5; lanes 4，10 and 16: prepared from cell suspension of McF 4; 
lanes 5, 11 and 17: prepared from cell suspension of McF 3; lanes 6, 12 and 18: 
prepared from cell suspension of McF 2. 
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Control strains [ATCC 25923 and MRSA (#3)] were included in each batch of PFGE. 
The pulsotypes of these strains obtained from each gel were compared by using the 
Dice band-based similarity coefficient with optimization and band tolerance of 1%. 
A dendrogram of these pulsotypes were generated by unweighted pair-group method 
by using average linkages (UPGMA) (Figure 3.6). Almost 100% identity was 
obtained. Isolates belonging to each of the two clusters indicated the 
reproducibility of the profiles and that variation in patterns between different gels 
should be minimal, except for one run which may have been due to different batch of 
reagent used. 
3.4.2. Analysis of PFGE Profiles 
Three hundred and twelve isolates, 89 blood and 223 non-blood isolates, were typed 
by PFGE (Table 3.4). Five PFGE types, A-E were identified (Figure 3.7) and 
included 273/312 (87.5%) MRSA isolates from 1988-2000 (Table 3.5; Table 3.6; 
Table 3.7) whilst the remainder 12.5% (37/312) isolates gave unique PFGE profiles. 
Among all the PFGE types, type A and B were predominant and constituted 68% and 
130/0，respectively of all isolates typed with PFGE. Type A strains, together with 38 
subtypes with minor variations (1-3 bands) in the PFGE patterns, included 211 
isolates and were present throughout the 13 years (Table 3.5; Table 3.6). The 
predominant subtypes Ala and A2a represented 34% (72/211) and 17 % (35/211), 
respectively of type A strains. Type Ala was found in both blood and non-blood 
isolates between 1991-2000 whilst type A2a was found from 1988; but it seemed to 
become more prevalent from 1998. Greater than 90% (68/74) of the isolates with 
PFGE type A examined have the major antibiotic resistance pattern I (TEDGToCi). 
Type B strains ( 2 7 bands difference from type A), together with 19 subtypes, 
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Figure 3.6. Cluster analysis of control strains for PFGE 
ATC-AATCC 25923; IS12-MRSA(#3) 
Two clusters were obtained for two different strains. Almost 100% identity was 
achieved for the isolates belonging to each cluster. 
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PFGE  
Marker(PFGE) 
Q l ^ m m i ^ ^ l 99/1602 99 A1 
94/4112 94 A2 
m H ^ ^ Q ^ I ^ ^ ^ 95/5136 95 B1 
H H P I H P I I I ^ ^ I 95/7092 95 B2 
^ H h fl ‘ " H f r ^ ^ l 9 _ 2 7 99 C1 
9 _ 5 6 98 D1 
97/5406 97 E 
^ H O m m H ^ I AT01128 ATCC 25923 
Figure 3.7. S'mal-digested PFGE profiles of the MRSA types and subtypes 
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Table 3.5 PFGE types 
Type No. of Subtype No. of Isolates Blood Non-blood 
N=312 N=89 N=223 
A 38 211 (68%) 55 156 
B 14 40 (13%) 19 21 
C 11 19 (6%) 7 12 
D 2 3(1%) 0 3 
E 0 2 (0.6%) 0 2 
Unique 0 37 (12%) 7 30 
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Table 3.6 Distribution of 312 MRSA isolates at PWH by PFGE types 
(1988—2000) 
a. Distribution of PFGE types in the years 1988-2000. 
PFGE No. of MRSA isolates for years 1988-2000 
Type 88 89 90 91 92 93 ^ V s % V s ^ ^ ~ [ j ^ 
A 3 1 6 11 15 13 20 26 23 23 28 20 22 211 
B 6 15 6 3 5 5 40 
C 1 2 1 2 3 1 1 3 3 2 19 
» 1 1 1 3 
E 丨 1 2 
^ 2 1 3 2 1 5 1 7 5 4 2 4 37 
Total P 1 3 2 1 5 1 7 5 4 2 4 4 ^ 
denotes unique PFGE profiles 
PFGE type A, B, C, D and E represents the type and subtypes. 
b. Distribution of predominant PFGE subtypes in the years 1988-2000. 
PFGE No. of MRSA isolates for years 1988-2000 
乃 Pe 88 89 90 91 92 93 94 95 96 97 9 8 ^ ~ 0 0 Ixotal 
A la 4 6 6 7 16 11 10 7 3 2 n 
Id 5 1 2 8 
2a 2 1 1 1 8 11 11 35 
1 2 1 7 11 
18a 1 1 4 1 2 9 
^ 1 1 1 4 1 1 2 11 
？ ^ 5 6 4 1 2 2 7o 
^ _ _ l a 1 3 2 6 
Total P 1 1 5 12 8 14 23 22 19 23 19 22 m 
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Table 3.7 Blood / Non-Blood ratio of major PFGE types 
PFGE Type Years Present Blood ; Non-blood 
A (and subtypes) 1988 - 2000 1 ： 2.8 (55/156) 
B (and subtypes) 1995-2000 1 ： 1.1 (19/21) 
C (and subtypes) 1988 - 2000 1 : 1.7 (7/12) 
(Total N=89/223) 
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included 40 isolates and were only present from 1995 to 2000 (Table 3.5; Table 3.6; 
Table 3.7). Fifty percent of type B isolates belonged to the predominant Bla 
subtype. Forty-seven percent (19/40) of type B isolates were blood isolates and 52% 
(21/40) were non-blood isolates and the blood versus non-blood ratio was 1:1.1，the 
lowest among all PFGE types (Table 3.7). These isolates have an antibiotic 
resistance pattern II，TEGToCiNM or related minor patterns, such as TEGToCiM，or 
TEGToCiNMR These isolates were characterized by their susceptibility to 
clindamycin, and resistance to mupirocin, and or netilmicin, or and or fusidic acid. 
Type C strains ( 2 4 bands difference from type A), together with 11 subtypes 
included 19 isolates comprising 6% of all isolates examined (Table 3.5; Table 3.6, 
Table 3.7). Thirty-seven percent (7/19) were blood isolates and 63% (12/19) were 
non-blood isolates. These isolates mainly carry unique antibiotic resistance patterns, 
and a few isolates belonging to antibiotic patterns I，IV, and VI (Table 3.3). Type D 
and type E only included 3 and 2 isolates respectively. The remaining 12.5% 
(37/312) of the MRSA isolates have unique PFGE profiles and are often also 
characterized by unique antibiotic resistance profiles, thus, representing the sporadic 
isolates. 
The dendrogram of relatedness of 312 MRSA isolates from PWH is shown in Figure 
3.8. Three clusters were obtained by using Dice coefficient and 1% band and 
position tolerance. All isolates with PFGE type A, including all subtypes, fell into 
850/0 similarity. Isolates belonging to PFGE subtypes A1 and A2 fell within 89% 
similarity. 
All twenty-one reference strains have unique PFGE patterns and are shown in Figure 
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3.9. The dendrogram of representatives from major PFGE types isolates, namely 
Al, A2, Bl, CI, D1 and E，and the reference MRSA strains is shown in Figure 3.10. 
EMRSA 1 has identical pattern to our PFGE Type A2. Moreover, EMRSA 9 has 
high similarity level (82%) to our isolates was related to PFGE type B. EMRSA 4， 
EMRSA7, EMRSA 11 and the Brazilian clone were clustered together and had the 
similarity level of 72% to our isolates. The other reference strains have low 
similarity to the MRSA isolates from PWH (similarity < 70%). 
Representatives from each of the PFGE types and subtypes and from different years 
were selected for further analysis by other typing method, including PCR-RFLP for 
coa gene, MLST, AFLP and Phage typing. The number of selected isolates from 
each of the PFGE types is listed in Table 3.8. 
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Figure3.8 Dendrogram of »SmflI-digested PFGE profiles of 
MRSA isolates (Dice, 1% Optimization & position tolerance; 
UPGMA) 
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*A，B，C, D, E indicate the major PFGE type and their subtypes; A1 and A2 indicate two 
subtypes of PFGE type A. 91 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Figure 3.9a PFGE profiles of Smal macrorestriction fragments of EMRSA isolates. 
Lanes 1，10 & 20:入-DNA PFGE markers; lane 2: ATCC 25923; lanes 3-9: EMRSA 
1-7; lanes 11-19: EMRSA 11-16. 
1 2 3 4 5 6 7 8 9 1011 1213 
Figure 3.9b PFGE of Smal macrorestriction fragments of MRSA international 
clones and major PFGE type isolates from this study. 
Lanes 1 & 13: A.-DNA PFGE markers; lane 2: ATCC 25923; Lane 3: representative 
of Brazilian clone (HSJ216); lane 4: representative of Iberian clone (HPV107); lane 
5: representative of New York/Tokyo clone (BK2464); lane 6: representative of 
Pediatric clone (HDE288); lanes 7-11: representatives of major PFGE types of 
MRSA isolates from this study, namely Ala, Bla, Cla, D1 & E respectively. Lane 
12: internal control strain (MRSA #3). 
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Figure 3.10. Dendrogram of 5>wal-digested PFGE profiles of international MRSA 
clones and the major PFGE types from PWH. (Dice: 1% optimization & position 
tolerance; UPGMA) 
* Al indicates Ala; A2 indicates A2a; Bl indicates Blaand CI indicates Cla. 
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Table 3.8 No. of MRSA isolates selected from different PFGE types for 
further analysis (see Appendix V for details) 
PFGE No. of MRSA isolates selected from different PFGE types for further analysis 
Type 88 89 90 91 92 93 94 95 96 97 98 99 0 Total 
A 2 1 5 7 5 6 10 8 7 11 9 7 6 84 
® 2 7 2 3 4 4 22 
C 1 2 1 2 3 1 1 1 2 2 16 
D 1 1 1 3 
E 1 1 2 
Total 3 4 6 9 5 9 11 10 14 15 14 14 13 127 
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3.5. Amplified Fragment Length Polymorphism 
One hundred and twenty-seven MRSA isolates were selected based on their PFGE 
types (Table 3.8). Representatives of each PFGE type were chosen from different 
years and included blood and non-blood isolates. The AFLP patterns of EMRSA 
1-16 and four international MRSA clones were also examined and compared against 
with the results obtained from Grady et.al.63 
The ALF data from the electrophoresis collected by ALFexpress were converted to 
Tiff format for analysis. Each MRSA isolate produced approximately 70 fragments 
ranging in size from 50 to 350 bp. About 70% of the fragments were smaller than 
200 bp (Figure 3.11). Percentages of optimization and band position tolerance for 
cluster analysis were optimized to be 0.1% and 0.3 % respectively to obtain the 
optimal separations of the MRSA isolates examined whilst the closely related isolates 
still cluster together. All of the MRSA isolates at PWH examined by AFLP were 
within the similarity level of 94% which was the similarity cut off level 
recommended by Hookey et. and were considered to be identical (Figure 3.12). 
Representatives of the EMRSA 1,4, 7, 9 and 11 fell within the same cluster of the 
MRSA isolates at PWH whilst the rest of the EMRSA and the international MRSA 
clones clustered separately. These five EMRSA were considered to be closely 
related to the MRSA isolates at PWH based on their AFLP fingerprints. 
Using the similarity cut-off level at 94%, the 16 EMRSA fell into six clusters (Figure 
3.13). Cluster 1 contained EMRSA 2，EMRSA 5，EMRSA 6，EMRSA 8 and 
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EMRSA 10. Cluster 2 only included EMRSA 15. Cluster 3 contained EMRSA 12， 
EMRSA 13 and EMRSA 14. Cluster 4 contained EMRSA 1，EMRSA 4，EMRSA 7, 
EMRSA 9 and EMRSA 11. EMRSA 3 and EMRSA 16 were clustered into two 
different groups: cluster 5 and cluster 6. This cluster analysis was very similar to 
the fluorescent AFLP study of epidemic MRSA done by Grady, et.al.^' except they 
grouped the isolates from cluster 1 and 3 together. 
The AFLP patterns of EMRSA 15 obtained from my experiment was also compared 
with the published EMRSA 15 pattem^^ visually and 89% (67/75) of the fragments 
were matched between these two fingerprints of EMRSA 15 obtained from two 
different AFLP procedures. 
The inter- gel variability and reproducibility of the AFLP were examined using three 
control strains (ATCC 25923, EMRSA 15 & MRSA # 34) and data were compared 
using Dice similarity coefficient and Pearson product-moment correlation coefficient. 
As shown in Figure 3.14a and b, comparison using Dice similarity coefficient 
resulted in higher relatedness within the same strain than using Pearson 
product-moment correlation coefficient for analysis. For example, the level of 
similarity between three samples of EMRSA 15 ran on three different gels was 
greater than 99% when using Dice coefficient; but it was only 93% when using 
Pearson coefficient. When the peaks of these samples were compared visually, they 
almost had the same peaks at the same position but varied with the intensity of the 
peaks. As the calculation of Pearson coefficient requires the consideration of both 
position differences of the peak as well as the intensity, this was not used for 
evaluation. The Dice coefficient only takes into account of the presence or absence 
of bands and is more suitable for analyzing the data generated from the ALFexpress 
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(Amersham Pharmacia Biotech, USA). Therefore, auto-search band function was 
used to search the fragments produced from AFLP and the similarity between 
samples were calculated by using Dice coefficient. 
Intra-gel comparison was done on EMRSA 15 and the result was shown in Figure 
3.14c. The similarity level was at 99.3%. 
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Figure 3.11 Image of AFLP pattern of MRSA isolates. 
42 
Lanes 1,7,13,19,25,31,37 and 42, molecular size marker containing ALFexpress 
sizer (50-500 bp) and a Cy-Iabeled oligonucleotide (75bp); lane 2, MRSA (#34); lane 
39, ATCC 25923; lanes 40 & 41, EMRSA 15; all other lanes, MRSA isolates from 
PWH. 
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Figure 3.12 AFLP dendrogram of MRSA isolates and EMRSA 
(Dice, Optimization : 0.1%, Band tolerance: 0.3%) 
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Figure 3.13. Dendrogram of cluster analysis of EMRSA 1-16. (Dice, 
Optimization: 0.1%, Band Tolerance: 0.3%) 
Six clusters were identified: cluster 1 included EMRSA 2，5，6 & 8; cluster 2 
included EMRSA 15; cluster 3 included EMRSA 12, 13, & 14; cluster 4 included 
EMRSA 1，4, 7，9 & 11; cluster 5 included EMRSA 3 and cluster 6 included EMRSA 
6. 
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Figure 3.14 Inter-lIntra-gel comparison of AFLP 
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Figure 3.14a. Inter-gel comparison using Dice Similarity Coefficient 
93.4% 
Figure 3.14h. Inter-gel comparison using Pearson product-moment Correlation 
Coefficient 
eI5=EMRSA 15; 34=MRSA#34; ATCC=ATCC 25923 




--- - - --- - - - --- ----------
tlL-- 11 1I11 Ill""" 111 11 "1 1111 111 n~I IIII" 11 ~ "f~ 1I 1 t 3 (e 15-2) I 1111 " " II IIIII~"" IIII " II"I I~ II I" "il lrHl t 3 (e15-1 ) 
99.3% 
Figure 3.14c. Intra-gel comparison 
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3.6. Phage Typing 
One hundred and twenty-seven MRSA isolates belonging to different PFGE type 
(Table 3.8) were typed by phage typing. Phage types of sixteen EMRSA isolates 
and four international clones were also examined. 
The phage reaction was graded as strong lytic reaction, weak lytic reaction and 
inhibition. The phage typing patterns were interpreted by following the 
three-reaction-difference rule,'^ namely, that three major phage reactions (or three 
strong lytic reactions) were allowed before isolates could be considered distinct. 
Many of the isolates studied showed limited or no strong lytic reaction, such as 
inhibition or weak reaction. Two major phage patterns were identified among the 
tested MRSA isolates from PWH. 
Most of MRSA isolates reacted to lytic group III or III + 1. The two major phage 
types were designated as type I and type II，which included 90 isolates and 36 
isolates respectively. The major difference between these two phage types is the 
strength of reaction. Isolates with phage type I mainly had inhibition while isolates 
belonged to type II showed strong lytic reaction and reacted more with group III 
phages (Table 3.9). The most common pattern of type I was 6/47/54/85 (underscore 
indicates inhibition reaction). Variants of type I showed different level of reactivity 
to these three phages plus or minor phages 75, 77 and 84，such as 6/47/54/85. 
6/47/54/75/85 and 6/47/77wk/54Z^. Ninety-two percent (83/90) phage type I 
isolates were susceptible to phage 6; 91% (82/90) were susceptible to phage 85; 88% 
(79/90) were susceptible to phage 47; 64% (58/90) were susceptible to phage 54; 
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52% (47/90) were susceptible to phage 75; 38% (34/90) were susceptible to phage 84; 
34% (31/90) were susceptible to phage 77. A few type I isolates also reacted to 
other phages such as 42E, 83 A, 81. No specific pattern was found to be dominant 
for type II isolates but they tended to react equally well to all phages in group III (6, 
42E，47, 53, 54，75, 77, 83A, 84，85). More than 50% of type II isolates were 
susceptible to these phages. All the type II isolates were susceptible to phage 47 
and 54. Fifty-eight percent of type II isolates also reacted to phage 81. Type II 
isolates showed more reactivity to lytic group I phages, such as 29，79 and 80. 
More than 20% of MRSA isolates at PWH examined for phage typing reacted to lytic 
group III phages and less than 10% of these isolates reacted to lytic group I phages. 
MRSA isolates belonging to phage type I included isolates with PFGE type A, C, D 
and E whilst majority of isolates belonging to phage type II were PFGE type B 
(Table 3.9，3.10). Although a few isolates with PFGE type A or C also gave similar 
reactions to isolates with PFGE type B, the latter ones usually showed both strong 
lytic reaction and inhibition reaction instead of confluent lysis. Figure 3.16 shows 
the images of different phage patterns with their PFGE types. A small number of 
isolates belonging to phage type II also belonged to PFGE type A, C, and D and were 
present before 1992. 
All EMRSA were successfully typed by the international set of phages and they all 
gave the expected reactions. However, the phages of international set itself was not 
adequate to distinguish all types of EMRSA and required additional phages 88A, 90, 
83C and 932. The international set was able to phage type the Iberian clone (85) 
and the New York/Tokyo clone (47/54/75/83A); but the Brazilian clone only gave 
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Figure 3.15. Distribution of major phage types of MRSA at PWH (1988—2000) 
(N=127) 
Type I & II denote the phage types. 
NBC denotes Non-blood culture; BC denotes blood culture. 
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inhibition reactions at lOOOx RTD and the Pediatric clone was nontypable by this set 
of phages. Based on the reactions of these reference strains obtained from this 
study, EMRSA 1, 4, 6，7, 8, 9, 11 and Iberian fell into the category of phage type I. 
The reproducibility of the reactions and interpretation of four strains, namely 
EMRSA 3 & 16 & MRSA # 20 & 22，were examined on different occasions, using 
different batches of cell suspensions prepared from the same culture broth, different 
media and culture broths from different days. Excellent results in terms of good 
reproducibility of strong reaction and limited variation on weak or inhibition reaction 
were obtained. 
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Figure 3.16 Images of different phage patterns 
(PFGE Type)::(Phage Type & Phage Patterns) 
Major lytic reactions are shown in black with slash separating from each other. 
Weak or inhibition reactions are shown in grey with under scoring the inhibition 
reactions. 
A::I liiliibttloii 6/47/54/75/85/81 B::II 29/42E/47/53/54/75/77/83A/84/85/81 
(inhibition 3A/3C/94) 
•P^iggj"If^S B S ^ ^ ^ ^ ^ ^ S i 
C::I Io!iibiti(»i 52A/6/42.E/47/54/75/77/85 D::II 42E/47/54/75/81 (inhibition 腿 
_ 
E::l 85 (iiihibldoii 47/54/75) rai 
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Table 3.9 Phage pattern of Type I & II vs. phage patterns of reference 
strains 
Lytic group I Lytic group II Lytic group III V  
52 42 83 
29 52 A 79 80 3A 3C 55 71 93 6 E 47 53 54 75 77 A 84 85 81 94 96 Sample PFGE Type Ph^e Type 
i i W m : 一 ^ r " JKl 95/5136 PII^^H BT"! 99/4027 C1 llfPI | | H i J B 98/0556 
國 議 97/5406 E I 
• EMRSA 1 B H B vf l • • EMRSA 2 
I ^ H EMRSA 3 
n EMRSA 4 • l l p H H B H H i U B S EMRSA 5 
P B M S B t EMRSA 6 
• • ^ H ^ H EMRSA 7 
• • EMRSA 8 Pll • • EMRSA 9 
[ '^ ^^^mHPBll EMRSA 10 
I H H EMRSA 11 
^ I • W M m I L EMRSA 1 2 
• HHjjH p i EMRSA 13 
_ W • EMRSA 14 
I EMRSA 15 
• H ^JHjHH EMRSA 16 
_ • • • • • • _ BraziUan' 
^ ^ ^ B i Iberian 
• i ^ B • ny特。  
I Pedatric'  
—Inhibition _ Weak reaction Strong reaction 
1 The Brazilian clone was not typable at lOOx. The reaction shown was at 1000 
RTD. 
2 The Pedatric clone was not typable at both lOOx and lOOOx RTD. 
The samples were labeled as: sample nameno. of culture broth一no. of plate 
e.g. 22—1—1 
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Table 3.10. Correlation of phage types and PFGE types 
PFGE Type 
Phage Type No. of Isolate A B C D E Present Year 
I 90 73 0 13 2 2 1988-2000 
II 34 9 21 3 1 0 88-91; 95-00 
Total No. of MRSA isolates at PWH typed by Phage typing was 127. Three isolates 
produced unique phage patterns. 
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3.7. Other Typing Methods 
3.7.1. PCR Restriction Fragment Length Polymorphism for the 
Coa Gene 
3.7.1.1. Optimization of PCR Conditions for the Coa Gene 
The PCR reaction was optimized by varying the template concentration (Figure 
3.18a), primer concentration (Figure 3.18b), polymerase concentration and different 
brand of polymerase [Taq (Amershem Pharmacia Biotech, USA) versus Hotstart™ 
(Qiagen, Germany) (Figure 3.18c) and DNA polymerization mix (Figure 3.18d). 
Although the Hotstart^^ polymerase (Qiagen, Germany) gave a stronger reaction in 
comparison with the Taq polymerase (Amershem Pharmacia Biotech, USA), the 
difference was not significant, the Taq polymerase (Amershem Pharmacia Biotech, 
USA) was chosen for economic reason. The annealing temperature at 48°C and 
50°C produced good amplification but a higher temperature gave more specific 
reaction and so 50°C was chosen. 
3.7.1.2. Analysis of MRSA by PCR-RFLP of the Coa Gene 
Isolates representative of the different PFGE types, Ala, A2a, A19a, Bla, Cla and U 
were examined by PCR-RFLP of the coa gene. ATCC 25923 was used as positive 
control. Positive PCR products of approximate 600 bp in size were obtained from 9 
isolates examined (Figure 3.19). After digestion with Alid, only one RFLP pattern, 
which included three fragments of sizes approximate 78 bp，125 bp and 310 bp, was 
obtained (Figure 3.20). As the RFLP patterns were identical and the previous report 
suggested that comparisons of the nucleotide sequence variations of the highly 
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variable repeated region of the coagulase gene could be an alternative method for 
1 0 o 
typing S. aureus. The PCR products of six MRSA isolates at PWH with different 
PFGE types, namely Ala, A2a, Bla, CI a, D1 and E respectively, and the four 
international MRSA clones were sent out for sequencing (Tech Dragon Limited, HK) on 
the ABI 3700 DNA analyzer (Applied Biosystems, USA) for the coa gene using 
primer pairs as for the PCR reaction. All six sequences of 537 bp of MRSA isolates 
at PWH were more than 98% identical. The sequence was then compared with the 
existing coa sequences of S. aureus in GenBank and found to be identical to the 
504bp coa gene of S. aureus, strain Stp28 (AB042587).^^ Analysis of this sequence 
by Alul digestion using online program (Webcutter 2.0， 
http://www.ccsi.com/firstmarket/firstmarket/cutter/cut2.html) will cut this 537 bp 
sequence at the position of 348 and 428 and confirmed the digestion to fragments of 
80，109 and 348 bps. 
Examination of the coa gene by restriction fragment length polymorphism appeared 
not to be discriminatory for studying the MRSA isolates at PWH and hence this 
method was not further investigated on the remainder of the isolates. However, the 
sequence of one of the MRSA isolates at PWH was compared with the coa sequences 
of the four international clones and the existing coa gene sequences of the British 
EMRSA obtained from GenBank. Pairwise comparison of the sequences was done 
on the online program (http://www.embl-heidelberg.de/) (Appendix III). The 
phylogenetic analysis was performed using the computer software Lasergene 
(DNAstar, USA) and found that the MRSA isolates at PWH was closely related to 
EMRSA 1,4 and 7 and the Brazilian clone (Figure 3.21). 
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Figure 3.18 Optimization of PCR-RFLP for coa gene 
a. Template concentration b. Primer concentration 
M 1 … 2 ^ 1 5 … 1 0 ^ 1 NR M 1 0.7 0.5 0.4 0.3 0.2 O.luM 
wmmm wmm 
Mm 
C. DNA Polymerase d. DNA Polymerization Mix Cone. 
M 2 3 4 5 6 7 8 9 M NR N 250 200 150 100 50 20nM •m •••• ••i WKm 
Lane 2-5 are samples using Tag (Amershem Pharmacia Biotech, USA); 
lane 6-9 are samples using Hotstart™ (Qiagen, Germany). 
M: Molecular Marker 
N: Negative Control (Coaguiase negative Staphylococcus aureus) 
NR: Negative Control (Reagent control) 
The concentrations shown in red were the choice of different parameters. 
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Figure 3.19. PCR for coa gene. 
Lane 1: (|)-174 JMPJHae III Marker; lane 2: ATCC 25923; lane 3: PFGE Ala; lane 4: 
PFGE A2a; lane 5: PFGE A19a; lane 6: Bla; lane 7: PFGE Cla; lane 8: PFGE U; 
lane 9: Negative control; lane 10: water control; lane 11: reagent control. 
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Marker ATCC Ala Bla Cla U 
i25bp ^ m u m m ^ m m ^ m m ^ ^ ^ ^ n ^ 
Figure 3.20 RFLP Pattern of isolates from different PFGE types. 
Lane 1: Lambda DNA-Hind III/ ([>-174 DNA-//ae III Digest; lane 2: ATCC 25923; 
lane 3: PFGE A la; lane 4: PFGE Bla; lane 5: PFGE Cla; lane 6: PFGE U. 
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Figure 3.21 Relatedness of coa gene sequences of MRSA isolate at PWH (PFGE 
type Al) and the reference strains. This is the phylogenetic tree of coa gene 
sequences of the PWH MRSA (PFGE type Al) isolate (537 bp) and international 
clones and the British EMRSA (the EMRSA sequences were obtained from 
GenBank). Our MRSA isolates are closely related to EMRSA 1, 4, 7 and the 
Brazilian clone. 
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3.7.2. Multilocus sequence typing 
MRSA isolates from different PFGE types and from 1988 to 2000 were typed by 
MLST. Preliminary results found that our major clone (PFGE type A and subtypes) 
belonged to sequence type 239 (allelic profile 2-3-1-1-4-4-3) which is the same as 
EMRSA 1，4 and 11 and also the Brazilian clone. A complete report on all the 
different isolates from different PFGE types will be available later and more 
comprehensive conclusion will be made. 
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Chapter 4 Discussion 
4.1. Evaluation of Typing Methods for MRSA 
Six different typing methods, namely, antimicrobial-susceptibility test and phage 
typing, pulsed-field gel electrophoresis (PFGE), PCR-restriction fragment length 
polymorphism for coaguiase gene (PCR-RFLP-coa) and sequencing, amplified 
fragment length polymorphism (AFLP) and multi-locus sequence typing (MLST), 
were investigated for the MRSA isolates at PWH. 
4.1.1. Antibiotic Susceptibility Testing 
The two predominant clones of MRSA from PWH were uniformly resistant to a 
number of antibiotics. Ninety-nine percent of the MRSA examined were resistant 
to erythromycin; 97% were resistant to tetracycline; 95 % were resistant to 
gentamicin; 94% were resistant to tobramycin; 89% were resistant to ciprofloxacin 
and 77 % were resistant to clindamycin. Antibiotics with low rates of resistance by 
the MRSA strains (< 10%), included fusidic acid, rifampicin, co-trimoxazole and 
chloramphenicol, may be useful in combinations for treatment of MRSA infection in 
certain clinical setting, such as chronic osteomyelitis and meningitis. Sixteen 
antibiotic resistant patterns were obtained in all MRSA isolates examined and the 
predominant pattern (TEDGToCi) was found in 46% of these MRSA isolates. 
An antibiotic panel with the combination use of clindamycin, erythromycin, 
mupirocin, netilmicin, fusidic acid and rifampicin will allow discrimination of the 
predominant clone from PFGE type B and other sporadic strains. 
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Detection of inducible resistance, such as for erythromycin and clindamycin, has to 
be detected by a close-disc approximation method. Loss or gain of resistance genes 
can be occur with different subcultures of the same isolates or in genetically related 
isolates. A major drawback of this method is the variability of borderline zone sizes 
which may be interpreted as susceptible or resistant on repeated samples. 
4.1.2. Phage Typing 
All the MRSA isolates from PWH and the British EMRSA were typable at lOOxRTD 
by this method. The Brazilian clone was only typable at lOOOx RTD whilst the 
Pediatric clone was not typable at both dilutions. Two major phage types were 
obtained among the MRSA isolates examined; one mainly associated with PFGE 
type A and C whilst the other was associated with PFGE type B. Phage typing can 
be used to distinguish the two major clones isolated at this hospital and can be useful 
as a screening method for detecting epidemic strains; however, it is not practicable to 
maintain a set of phages in the hospital for it will be too labour intensive. 
The reproducibility of this method is very good and minor variations of the test 
procedure could be tolerated without affecting the result. For example, testing 
bacteria at different stages of growth, such as grown for 4 hours or 16 hours 
incubating in broth culture at 37°C, did not alter the test result. This method would 
be easier to perform with the aid of the Lidwell multi-inoculator;"^ but, application 
of the phages with an auto-pipette was acceptable, although more time-consuming. 
However, grading the lytic reaction is subjective, especially the inhibition reaction, 
and experience and consistency in grading is essential and preferably with one 
trained operator in the clinical laboratory. Overall the results were easy to interpret 
but the discriminatory power of this method is moderate. 
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4.1.3. Pulsed-field Gel Electrophoresis 
All the MRSA isolates examined were typable by this method and 5 major PFGE 
types, 61 subtypes and 37 unique types were obtained from 312 MRSA isolates from 
PWH. EMRSA 1 showed an identical PFGE pattern to our PFGE A2a and ERMSA 
9 fell into the B cluster. Other EMRSA, including EMRSA 4, 7, and 11 may also be 
related to our MRSA isolates. 
The results of this method are reproducible but will be sensitive to any genetic 
changes including the changes caused by multiple subculturing and evolutionary 
changes over a prolonged period. Difficulties with inter-gel comparison and 
lab-to-lab comparison may be caused by different batches. The instability of the 
electrophoresis machine will affect the resolution and migration of the fragments and 
also decrease the reproducibility of the method. The method is moderately easy to 
perform but the procedure requires multiple steps and is lengthy. 
The most difficult part regarding this method is the interpretation of the PFGE 
patterns especially when using Tenover's criteria'^^ for interpreting PFGE patterns 
for longitudinal analysis rather than outbreak investigation. Though PFGE for S. 
aureus often produced less than 20 fragments, counting the number of bands and the 
possible genetic changes could be subject to observer variation. Establishing a 
systematic and consistent way to interpret the PFGE fragments by using computer 
software is essential to select all the true fragments and eliminate all the misclassified 
bands. For example, in this project, I first used the auto-band searching function of 
a computer software BioNumerics version 2.5 (Applied Maths, Belgium), to select 
the most "true" bands with the least "false" bands caused by artifacts. However, 
manual adjustment of mis-assigned bands was still required. The patterns of the 
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control strains included in each gel are thus important to distinguish a true missing 
band at a position from a false missing band caused by gel variation. Also 
difficulty was encountered with bands which were too close together to identify 
whether they were to two separate bands or one single band. Tenover's criteria^ ^ ^ 
were useful for interpreting PFGE patterns for studying small sets of isolates (< 30) 
and for outbreak studies! 54 but the dendrogram generated was better at resolving the 
relatedness when a large number of isolates was compared. 
PFGE is discriminatory and could be applied for typing MRSA in the hospital setting 
and can be used as a confirmatory method. 
4.1.4. Amplified Fragment Length Polymorphism 
All the MRSA isolates examined were typable by this method. The discriminatory 
power is much less than PFGE and only 1 major AFLP cluster was obtained for all 
127 MRSA isolates examined which included isolates from different PFGE types. 
EMRSA 1, 4, 7, 9 and 11 also fell within this cluster and is correlated with the PFGE 
result. This method may be more useful for typing bacteria with large genetic 
diversity, such as gram negative bacteria, including Acinetobacte/^ and 
Salmonella的but, for bacterium which exhibits limited genetic diversity, such as 
MRSA90 discrimination between strains is more difficult. 
The reproducibility of this method is good especially with the application of 
advanced electrophoresis equipment which has a good standardizing system for 
inter- and intra- gel comparison and produces a data file analyzable by other data 
analyzing software. For example, the ABI DNA analyzer 377 (Applied 
Biosystems, USA) has a set of internal size markers labeled with a separate dye that 
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run along with each sample lane to correct the differences in run speed between the 
individual runs or between different lanes and the ABI system is able to perform 
such calibration automatically. These inline reference markers make the 
normalization of gel much more consistent than the traditional reference markers 
which are run on separate lanes and only a few times per gel. In this study, the 
ALFexpress (Amershem Pharmacia, Biotech) was used but the company only 
provides ALFexpress size marker between 50 - 500 bp with 50 bp apart from each 
step. Though a standard point of 75 bp was added in order to increase the standard 
points for normalization, minimal improvement was observed. Moreover, the ABI 
system has unique features to capture maximum signals from each sample uniformly 
and allowed the possibility of performing comparison analysis by using Pearson 
correlation with little adjustments. In addition, the data file generated from ABI is 
transferable directly to BioNumerics version 2.5 (Applied math, Belgium) for further 
analysis instead of the necessity of transferring the data file to a TIFF format and 
then importing to the software (e.g. ALF file generated by ALFexpress). Multiple 
transfers of data increase the possibility of losing data points and diminish the 
reproducibility and discriminatory power of the method. In addition, a requirement 
for multiple procedural steps may increase the possibility of human error or 
variations in procedure which could lead to decreased reproducibility. 
4.1.5. PCR-Restriction Fragment Length Polymorphism for the 
Coa Gene 
Only one identical RFLP pattern was obtained from representative isolates of PFGE 
A，B，C, D, E and U after PCR and Alul digestion. Hence the discriminatory power 
of this method is low in our setting for typing MRSA isolates. A phylogenetic 
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analysis was drawn to compare the known coa sequences of the British EMRSA with 
the MRSA isolates at PWH and the four international MRSA clones and it showed 
that the MRSA isolates from PWH were highly closely related to EMRSA 1,4, 7 and 
the Brazilian clone based on the comparison of coa gene sequences. 
4.1.6. Multilocus Sequence Typing 
Multilocus sequence typing has been considered to be more suitable than PFGE for 
longitudinal and global epidemiological study due to its high discriminatory power 
with indexes variation accumulating more slowly than PFGE.54 MRSA isolates 
from different PFGE types and from 1988 to 2000 were typed by MLST. The 
MLST procedure was performed at the Department of Biology and Biochemistry, 
University of Bath, UK. Part of the procedure, including DNA extraction, PCR for 
seven housekeeping genes on each isolates and PCR for sequencing, was performed 
during my attachment at the university; however, because of the shortage of time for 
attachment, and an automated sequencer was not available in the lab in Hong Kong, 
this part of the sequencing work and data analysis are still ongoing (in collaboration 
with Dr. M. Enright, at the Department of Biology and Biochemistry, University of 
Bath, UK). The preliminary data on the MLST patterns of the MRSA isolates at 
PWH showed that the major clone belonged to sequence type 239 which was 
identical to that of EMRSA 1, 4，11 and the Brazilian clone. The result was 
complementary to the results obtained by other methods, including PFGE, AFLP and 
coa gene sequence polymorphism. 
The advantage of this method is its unambiguous data on the allelic profiles which 
allow lab-to-lab comparison. The housekeeping genes chosen are relatively 
well-conserved and enable the evolutionary background of different MRSA to be 
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examined. The disadvantage of this method is that it is labour intensive and time 
consuming in performing the procedure as well as in data analysis. However for 
research laboratories with a high throughput automated DNA sequencer, such as ABI 
3700 (Applied Biosystems, USA), rapid generation of this data is possible. 
4.1.7. Conclusion for Method Evaluation 
In conclusion, antibiotic susceptibility test, phage typing and PFGE are useful for 
studying the MRSA isolates at PWH. PFGE is the most discriminatory method 
whilst antibiotic resistant pattern is the most rapid, easy and inexpensive method for 
outbreak studies or infection control purposes. Phage typing could also 
discriminate the local strains but maintaining the phages may not be feasible in a 
routine diagnostic laboratory. AFLP and coa gene polymorphisms were acceptable 
for comparison between MRSA isolates obtained from diverse geographic locations 
but their resolution is too low for strain typing within one hospital where strain 
diversity is limited. MLST is more stable and comparative than PFGE; but, it is 
again more suitable for evolutionary and population studies in different geographic 
settings. Among the molecular typing methods investigated in the study, PFGE 
shows the highest discriminatory power whilst the PCR-RFLP of the coa gene has 
the least. Overall, good correlation between these four molecular typing methods 
mentioned above is observed based on the similar conclusion drawn from the 
relatedness between the MRSA isolates at PWH and the British EMRSA. 
Phenotypic typing methods are much easier than the molecular typing methods to 
perform. They have their usefulness, such as in being a preliminary screening 
method, though they have less discriminatory power and can be subject to both 
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4.2. Analysis of results of Antibiotic Susceptibility 
Test, Phage Typing, PFGE, AFLP, PCR-RFLP 
(Coa) & MLST 
4.2.1. Correlation between Methods 
PFGE identified two major clones of MRSA from this hospital. The antibiotic 
resistance patterns were useful in distinguishing these two major clones of MRSA. 
Detection of resistance to a unique set of antibiotics with the combination of 
clindamycin, erythromycin, mupirocin, netilmicin, fusidic acid and rifampicin, may 
be used in the hospital as part of the infection control strategies to discriminate and 
alert the presence of PFGE group B MRSA and other unique strains and allow 
appropriate interventions to be made regarding infection control measures. 
Good correlation between the results of PFGE and Phage typing was found. Most 
of the MRSA isolates of PFGE type A also belonged to phage type I whilst the 
MRSA isolates of PFGE type B belonged to phage type II (Table 4.1). Moreover, 
by using only group III phages, it is also possible to distinguish the PFGE type A and 
type B isolates because the isolates in this hospital mainly reacted to the group III 
phages and PFGE type B isolates tend to be much more susceptible to group III 
phages; however maintaining a set of phages in the hospital is labour intensive. 
Both AFLP and coa gene polymorphism analysis suggested that all MRSA isolates at 
PWH belonged to one big clone rather than two major clones as suggested by PFGE. 
The result of MLST also supported the result of AFLP though isolates with PFGE 
type B should be analyzed by this method for further confirmation. 
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4.2.2. Clinical Correlation 
The study has shown the evolution and establishment of predominant MRSA clones 
in our hospital in the last decade and the major clone was closely related to the 
British EMRSA 1 and 4. The demographics including name of patient, ID, age, 
ward and specimen types from which the MRSA isolates were cultured were 
obtained from the infection control unit, PWH and were analyzed by Dr. D. Lyon and 
Dr. M. Ip.95 The correlation between PFGE types and the MRSA isolation at 
different clinical units was examined. Strains belonging to PFGE type A and their 
subtypes were present in the hospital in late 1980s and finally established to be the 
predominant clone of the hospital in mid-1990s. They were isolated from the major 
units including the adult intensive care, medical and surgical units (Figure 4.1 & 4.2). 
Strains belonging to PFGE type B were present predominantly in SCBU (special care 
baby unit) in an outbreak between 1995—1997 (Figure 4.1)，though these isolates 
were still present in the Bums unit. The high prevalence of MRSA in these clinical 
units may be due to the increased patient contact and increase in procedures and the 
usage of medical device, such as intrvascular lines, which are often associated with 
the transmission of MRSA in the hospital. Handwashing is one the most important 
and recommended preventive procedures for eliminating the transmission of MRSA 
through health care workers."^^ The presence of these two clones in these units may 
explain the increase of bacteraemia cases in the late 1990s. However, detailed 
examination of the risk factors and statistical analyses would be required to confirm 
this hypothesis. 
The strains belonging to PFGE type C and D which have more than 3 bands but less 
than 6 bands difference from PFGE type A and would fall into the subtypes of PFGE 
type A if a 6 band difference cut-off is u s e d . Complementary use of other typing 
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No. of Bacteremic Episodes in Clinical Units at PWH, 1989-1999 
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Figure 4.1 The increase of MRSA isolates in ICU, medical & surgical units 
between 1988-1999 correlated well with the presence of PFGE type A isolates among 
these years. The rise of MRSA isolates in SCBU between 1995-1997 also 
correlated with the emergence of the PFGE type B isolates 95 
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No. of Patient Episodes of MRSA 1100 Deaths & Discharges in Clinical 
Units at PWH, 1989-1999 
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Figure 4.2. The concentration of MRSA was high in ICU throughout the years and 
correlated well with the presence of PFGE type A isolates. (Bums unit is not shown 
above, but showed insignificant numbers from the mid 1990s.)^^ 
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methods such as multilocus sequence typing (MLST), and SCCmec typing will 
enable further delineation of these isolates. 
4.2.3. Correlation between MRSA Isolates at PWH and the 
Representatives of the International Clones 
According to the PFGE result, our MRSA isolates with PFGE type A2a were 
indistinguishable from EMRESA 1 and closely related to EMRSA 4，7, 9, 11. 
Based on the AFLP fingerprints, EMRSA 1,4, 7, 9 and 11 were closely related to our 
MRSA isolates and fall in the same cluster which will fit into the cluster 4 of the 
different clusters among the EMRSA^' and the other international clones, including 
the Iberian clone, Brazilian clone, NY/Japan clone and Pediatric clone, were clearly 
falling into separate clusters. The phylogenetic analysis of coa gene sequences also 
suggested that EMRSA 1, 4 and 7 and the Brazilian clone were closely related our 
MRSA isolates. Moreover, the MLST classified our MRSA isolates in the same 
sequence type (ST239) as EMRSA 1, 4，11 and the Brazilian clone. Based on all 
these results, it can be concluded that our MRSA isolates were closely related to the 
British EMRSA especially EMRSA 1 and 4 and may have a clonal lineage similar to 
that of the Brazilian clone in evolutionary term.^^ 
The recent evolutionary study of MRSA based on the MLST profiles and SCCmec 
typing of 359 MRSA isolates collected between 1961 and 1999 from 20 countries 
postulated that MRSA isolates with ST239 belonged to a large genetic complex (CCS) 
which included three sequence types (ST8，ST250 & ST239) among related MSSA 
and MRSA clones. ST239 MRSA isolates were probably derived from ST8-MRSA 
isolate which was also derived from ST8-MSSA isolates through acquisition of the 
type III SCCmec. Almost all the MRSA isolates from 1960s (archaic clone) 
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belonged to Therefore, it could be proposed that not only our MRSA 
isolates are closely related to the British EMRSA, but also do they related to the 
archaic clone of MRSA identified from Europe. 
EMRSA 1 appeared in the early 1980s in England^^ and subsequently spread to other 
countries such as Spain， Hong Kong was a British colony before 1997 and the 
transmission and spread might have occurred in the 1980s between these places. In 
addition, PFGE type A2a was present in 1988 and was earlier than PFGE type Ala 
(present since 1991). From this point of view, PFGE type Ala might be a strain 
derived from A2a or EMRSA 1 who adopted the local hospital environment in early 
1990s and then established to be one of the predominant clones at the PWH. 
Besides Hong Kong, an Australian MRSA strain with the characteristics of EMRSA 
1 was also reported in 1984.'^ ^ 
4.3. Future Research 
Further investigation in two main areas will be useful to clarify the clonal 
relationship between the isolates at PWH and to characterize the MRSA strains in 
Hong Kong. First of all, the PFGE result suggested that MRSA isolates at PWH 
between 1988—2000 fell into two major clones; however, the result of AFLP and 
coa gene polymorphism proposed that all these isolates were closely related and 
belonged to one cluster. Therefore, the relationship between isolates with PFGE 
type A and type B should be further investigated by other genotypic typing methods, 
such as genetic background, SCCmec typing and c/aI-Tn544 to delineate further its 
evolutionary lineage. Moreover, genetic markers, including spak sequence and 
other MSCRAMM, will be valuable markers to characterize these strains. In 
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addition, MLST on PFGE type B isolates should also be evaluated. 
Secondly, MRSA isolates collected from other hospitals should be investigated in 
order to confirm the major epidemic MRSA from Hong Kong and that they were 
likely to be related to the British EMRSA. Moreover, investigation on MRSA 
isolates from neighboring regions or countries, such as Macau, Mainland China and 
Taiwan, may be useful to track the spread of the MRSA clone(s). 
4.4. Conclusion 
Changes in MRSA incidence are likely to be multifactorial, but the establishment of 
a dominant clone (PFGE type A) and the appearance of a new MRSA strain in 1995 
(PFGE type B) may explain in part the subsequent rise in MRSA cases and the 
disproportionate rise in MRSA bacteremia from 1995—2000. The dominant 
clone (PFGE type A) was demonstrated to be closely related to the British EMRSA, 
especially EMRSA 1 and 4. Further investigation by using other typing methods 
will be helpful to further delineate strains from PWH their evolutionary lineage. 
The typing methods used in this study showed different levels of discriminatory 
power and typability for studying the MRSA isolates at PWH. PFGE showed the 
highest discriminatory power whilst the PCR-RFLP for coa gene had the least. 
Antibiotic susceptibility test is an effective typing method for discriminating MRSA 
isolates at PWH with the combination use of clindamycin, erythromycin, mupirocin, 
netilmicin, fusidic acid and rifampicin in combination with PFGE may be applied as 
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Reagent & Material Lists for Methods 
a. Identification 
Material/Reagent Source Catalog No. 
Staph latex slide agglutination test Serobact, Australia M43 




Mannitol salt agar 
Mannitol Oxacillin salt agar 
b. Antibiotic Susceptibility Test 
Material/Reagent Source 
Oxacillin Oxoid, UK 
Tetracycline (T) Oxoid, UK 
Mupirocin (M) Oxoid, UK 
Netilmicin (N) Oxoid, UK 
Ciprofloxacin (Ci) Oxoid, UK 
Gentamincin (G) Oxoid, UK 
Fusidic acid (F) Oxoid, UK 
Tobramycin (To) Oxoid, UK 
Cotrimoxazole (S) Oxoid, UK 
Erythromycin (E) Oxoid, UK 
Chloramphenicol (C) Oxoid, UK 
Rifampicin (R) Oxoid, UK 
Clindamycin (D) Oxoid, UK 
McFarland Standard bioMerieux, France 
Antibiotic Disk Dispenser Oxoid, UK 
Blood Agar Plate 
Mueller Hinton Agar Plate 
BioNumerics 2.50 Applied Maths, Belgium 
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c. PCR for mecA gene 
Material/Reagent List Source Catalog No. 
GeneAmp PCR System 9700 Perkin Elmer, Applied Biosystem, USA 
Thermal Imaging System CTI-500 Amersham Pharmacia Biotech, Sweden 
Gel Electrophoresis Tank Amersham Pharmacia Biotech, Sweden 
MecA (forward primer) 
5'-TGGCTATCGTGTCACAATCG-5' GIBCOBRL, Life technolgies, USA 
MecA (reversed primer) 
5'-CTGGAACTTGTTGAGCAGAG-5' GIBCOBRL, Life technolgies, USA 
Taq D N A polymerase (5,000 U/ml) Amershem Pharmacia Biotech, USA 27-0799-61 
1 Ox PCR Buffer Amershem Pharmacia Biotech, USA 
D N A polymerization mix (20mM/dNTP) Amershem Pharmacia Biotech, USA 27-2094 
Seakem LE agarose BMA, USA 50004 
Lambda DNA-Hind III/ X-174 DNA-//ae III Digest Amershem Pharmacia Biotech, USA 27-4054 
X174 DNA/Hae III Marker Promega, USA G176A 
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d. Pulsed-fleld gel electrophoresis 
Material/Reagent List Source Catalog no. 
Sea P l a q u e G T G agarose (Low-mel t ing agarose) F M C BioProducts , U S A 50111 
Seaken Gold agarose ( P F G E agarose) F M C BioProducts , U S A 50150 
Chef M a p p e r BioRad, U S A 
Thermal Imaging System CTI-500 Amershem Pharmac ia Biotech, Sweeden 
Water ba th H A A K E , U S A 
BioNumer ics 2 .50 Appl ied Maths , Be lg ium 
Boric Acid Merk , U K K 2 4 3 9 2 1 1 5 805 
Bri j 58 (w/v) polyoxyethylene (0 .5%) Sigma, U S A P-5884 
E D T A Na2 Sigma, U S A E D 2 S S 
Eth id ium b romide 
M g C l j Sigma, U S A M - 8 2 6 6 
NaCl BDH, U K K22393733 542 
N-LauroyI sarcosine (Sarkosy NL30) Sigma, U S A L-9150 
N-Lauroylsarcosine (Sarkosyl N L 3 0 ) Sigma, U S A L-9150 
Sodium deoxycholate (w/v) (0 .2%) Sigma, U S A D-6750 
Tris Sigma, U S A T-1503 
Lysostaphin Sigma, U S A L-4402 
Lysozyme Sigma, U S A L-6876 
Prote inase K Amersham Pharmac ia Biotech , U S A E 7 6 2 3 0 Z 
Sma I Amersham Pharmac ia Biotech, U S A E 1 0 8 5 Y 
1 Ox T Buf fe r Amersham Pharmac ia Biotech , U S A 
0.1 % B S A Amersham Pharmac ia Biotech , U S A 
；I D N A - P F G E M a r k e r s A m e r s h a m Pharmac ia Biotech , U S A 27-4530 
Blood Pla te 
McFar land Standard b ioMer ieux , France 
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e. Amplified fragment length polymorphism 
M a t e r i a l / R e a g e n t List S o u r c e Cata log No . 
G e n e A m p PCR System 9 6 0 0 Perkin Elmer , USA 
P T C - 2 0 0 D N A Engine MJ Research, USA 
ALFexpress D N A sequencer Amershem Pharmac ia Biotech, Sweeden 
Lambda Bio 40 (UV/VIS Spectrometer) Perkin Elmer , USA 
Wate r bath H A A K E , USA 
BioNumer i c s 2 .50 Applied Maths , Be lg ium 
Wizard G e n o m i c D N A Purif icat ion Kit (Blood Samples) Promega , USA A l 120 
Nucle i Lysis Solution Promega , USA 
Rnase Solution Promega , USA 
Protein Precipitat ion Solution Promega , USA 
D N A Rehydrat ion Solution Promega , USA 
Lysozmye Sigma, USA L-6876 
Lysostaphin S igma, USA L-4402 
E D T A Sigma, USA E D 2 S S 
Isopropaiiol B D H , UK 15219 
Ethaiiol B D H , UK 10107 
M v e l (10 ,000U/n i I ) New England (BioLabs) , USA R 0 5 2 5 S 
lOx NE Buf fe r 2 New England (BioLabs) , USA 
l O O x B S A New England (BioLabs ) , USA 
M s e 丨 Invitrogeii，USA 
lOx R E A C T 1 Invitrogen, USA 
Eco Rl ( lOU/u l ) G I B C O B R L , Life technolgies, USA 15202-013 
lOx R E A C T 3 G I B C O B R L , Life technolgies , USA 
R N a s e Amershem Phaniacia Biotech, USA E 7 0 1 9 4 Z 
T4 D N A Ligase (5U/ii l) Amersham Pharmac ia Biotech, USA 7 0 0 0 5 Y 
lOx Ligation Buf fe r Amersham Pharmac ia Biotech, USA 
RI adaptor G I B C O B R L , Life technolgies , USA 
5'-CTCGTAGACTGCGTACC 
C A T C T G A C G C A T G G T T A A - 5 ' 
Mi-e I adaptor G I B C O B R L , Life technolgies , USA 
5 ' - T A C T C A G G A C T C A T C 
G A G T C C T G A G T A G C A G - 5 ' 
Cy5- labe led Eco RI pr imer G E N S E T , USA 
5 ' - ( C y 5 ) G A C T G C G T A C C A A T T C - 3 ' 
A/‘�’e I+C pr imer G I B C O B R L , Life technolgies , USA 
5 ' - G A T G A G T C C T G A G T A A C - 3 ' 
Taq D N A polymerase (5 ,000 U/ml) A m e r s h a m Pha rmac ia Biotech, USA 2 7 - 0 7 9 9 - 6 1 
IOjc P C R Buf fe r Amersham Pharmac ia Biotech, U S A 
D N A polymer iza t ion mix ( 2 0 m M / d N T P ) Amershem Pha rmac ia Biotech , U S A 2 7 - 2 0 9 4 
6 % EZ Squeeze Ge i i e -PAGE Plus 7M Urea Amresco , USA £ 5 6 8 
ALFexpress Sizer 50 -500 (5 fmol /u l ) Amersham Pharmac ia Biotech, U S A 27 -4539 -01 
Load ing Dye Amersham Pharmac ia Biotech, U S A 
Cy-5 labeled m a r k e r (75bp) G E N S E T , USA 
E D T A ( 5 0 n i M ) 
TE buf fe r 
T B E buf fe r 
7 0 % Ethaiiol 
Loading dye ( f o r m a m i d e + b romopheno l blue) 
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f. Phage typing 
Material/Reagent List Source Catalog no. 
Bacteriophages / Propagating Strains 
3 A / 8 3 1 9 PHLS 
3C / 8327 PHLS 
6 / 8509 PHLS 
2 9 / 8 3 3 1 PHLS 
42E / 8357 PHLS 
47 / 8325 PHLS 
52 / 8507 PHLS 
52A / 8363 PHLS 
53 / 8511 PHLS 
54 / 8329 PHLS 
55 / 8358 PHLS 
7 1 / 9 3 1 5 PHLS 
75 / 8354 PHLS 
77 / 8356 PHLS 
79 / 8363 PHLS 
80 / 9789 PHLS 
8 1 / 9 7 1 7 PHLS 
8 4 / 10455 PHLS 
85 / 10457 PHLS 
9 4 / 10970 PHLS 
9 5 / 10971 PHLS 
9 6 / 10972 PHLS 
8 3 A / 10039 PHLS 
Nutrient agar plate (with calcium chloride) 
Nutrient broth (Oxoid; No.2) Oxoid, UK CM67 
Sodium chloride 
Agar (Oxoid; No.l) Oxoid, UK LI 1 
Calcium chloride 
Nutrient broth (Oxoid; No.2) Oxoid, UK 
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g. PCR-Restriction fragment length polymorphism for coa gene 
Material/Reagent List Source Catalog No. 
G e n e A m p P C R Sys tem 9600 Perk in Elmer , Appl ied Biosys tem, U S A 
Thermal Imaging System CTI-500 Amersham P h a r m a c i a Bio tech , Sweden 
Gel Elec t rophores is Tank Amersham P h a r m a c i a Biotech , Sweden 
Water bath H A A K E 
Coa 1 ( fo rward p r imer ) 
5 ' - T A T A G A G A T G C T G G T A C A G G - 3 ' G I B C O B R L , Life technolgies , U S A lOpmole/ul 
Coa 2 ( reverse p r i m e r ) 
5 ' - C T G T A T G T C T W T G G A T A G A G - 3 ' G I B C O B R L , Life technolgies , U S A lOpmole/ul 
Taq D N A po lymerase (5 ,000 U / m l ) Amersham P h a r m a c i a Bio tech , U S A 27-0799-61 
1 Ox P C R Buf fe r Amersham P h a r m a c i a Bio tech , U S A 
D N A polymer iza t ion m i x ( 2 0 m M / d N T P ) Amersham P h a r m a c i a Bio tech , U S A 27 -2094 
Seakem LE agarose B M A , U S A 5 0 0 0 4 
M e t a P h o r agarose B M A , U S A 5 0 1 8 0 
Alu I (2 ,500 U ) Amersham P h a r m a c i a Bio tech , U S A 27-0884-02 
L a m b d a D N A - H i n d III/ X-174 D N A - / / a e III [ Amersham P h a r m a c i a Bio tech , U S A 27-4054 





Buffers & Media 
1. Buffers 
a. SE Buffer (PH=7.5; autoclaved; keep at 4°C) 
NaCl (75mM) 4.38g 
EDTA Na2 (25mM) 9.3g 
Distilled H2O Top up to IL 
b. Lysis Buffer 
i) Gram-positive Lysis Buffer (PH=?; keep at 4�C) 
Tris (6mM) 0.36g 
EDTANa2(100mM) 18.6g 
NaCl (IM) 29.2g 
Brij 58 (w/v) polyoxyethylene (0.5%) 2.5g 
Sodium deoxycholate (w/v) (0.2%) 1 .Og 
N-Lauroyl sarcosine (Sarkosy NL30) 8.25ml 
MgCb (ImM) 0.5ml (IM) 
Distilled H2O Top up to 500ml 
ii) Proteolysis Lysis Buffer (PH二9.5; keep at 4°C) 
N-Lauroyl sarcosine (Sarkosyl NL30) (1%) 5g/16.5ml 
EDTA Na2 (0.5M) 93g 
Distilled H2O Top up to 500ml 
c. TE Buffer (PH=7.5; autoclaved; keep at 4°C) 
Tris (lOmM) 1.21g 
EDTA Na2(10mM) 3.72g 
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Distilled H2O Top up to IL 
d. TBE Buffer (lOx) (keep at 4°C) 
Tris 108g 
EDTA Na2 7.44g 
Boric Acid 55.65g 
Distilled H2O Top up to IL 
2. Agarose 
a. Low-melting agarose gel (2%) 
Agarose 0.2g 
SE Buffer 10ml 
b. PFGE agarose gel (1%) 
Agarose Ig 
TBE Buffer (Ix) 100ml 
3. Media Plate 
s e e plate: Oxoid nutrient broth no.2 20g 
Sodium Chloride 5g 
Oxoid agar no. 1 7g 




CLUSTAL W ( 1 . 8 2 ) m u l t i p l e sequence alignment 
IBERIAN-CLONE.seq AOGATGGAACAnTGGATATG-AAGC-GAGACC 31 
EMRSA一6.SBQ CAGCTGGTACAGCTATCnniGMTACAAOGATGGMCATniGGATATG-AAGC-GAGAOC 58 
EMRSA_12.SEQ CAG-TGGTACAGCTATCCGTGMTACAACGATGGMCAnTGGATATG-AAGCCGAGACC 58 
EMRSA—2.SEQ CAG-TGGTACAGCTATCOniGMTACAAOGATGGMCAnTGGATATC-MGOG-AGAOC 57 
EMRSA一5.SEQ CAGATAACAC —GAA GGACATCTGGATATG-AAGC-GAGAOC 38 
EMRSA—10.SEQ CAG --TACAAOGATCGAACATniGGATATC-AAGC-GAGAOC 38 
EMRSA—16 .seq CAG -AAGCC-AAGC- 12 
MRSA—PWH一.seq - AOGA---TCGAACATITGGATAT--GAAGOGAGACC 31 
BRAZILIAN-CLONE.SBQ AGGA---TGGAACATITGGATAT--GAAGOGAGACC 31 
EMRSA_7.SEQ CAGA - ATACAAOG-TGGMCmTGGATATmGMGOGAGAC- 40 
EMRSA_4.SEQ CAGG GA -TTOAAGCTAGAC- 18 
EMRSA一 1 . SEQ CAGA - … … - AC- 6 
E M R S A � l . S E Q CAG TITGGATAT--GAAGOGAGAC- 22 
NY-JAPAN-CLONE.SEO - AOGA---TGGAACATmGGATA--TGAATOGAGACC 31 
PEDIATOIC-CLONE.SEQ - … … - AOGA---TGGA-CAnTGGATA--TGAACATGGACC 30 
EMRSA一14.SEQ TAC AGCAAGATC 12 
EMRSA_3.SEQ -CAG--GGATA--TGAAGOGAGACC 20 
EMRSA_13.SE0 CAG … T C M TGGAGACAAGATC 20 
EMRSA_15.seq CAG TGAA GT-AGACAAGATC 19 
EMRSA一9. SEQ CAGG-ATTAC- - -TCHT-GTAAAGA- - - -GACCAAATXTnTAG-TATT……--GACT 42 
IBERIAN-CLONE, seq AAGATTCAATAAGOC-ATCAGAAACAAATGCATATMOTrAACAACACATGCMATGCTC 90 
EMRSA一 6.SEQ AAGArrCMTAOOOC-ATCAGAAACAMTGCATATAAOnMCAACACATGCAMTGCTC 1 1 7 
EMRSA_12.SEQ AAGATTCAATAOOCCCATCAGAAACAAATGCATATMOCTMCAACACATCmATGgrc 1 1 8 
EMRSA一 2 .SEQ AAGAT-CAATAC-CCCATCAGAMCAAATGCATATMOCTMCAACACATGGAAACGG-- 1 1 3 
EMRSAJ.SEQ AAGATTCMTACGOC-ATCAGMACAAATGCATATMOGTMCMCACATGCAMTGCTrC 97 
EMRSA.IO.SEQ AAGATrCMTAAGCCT-TCAGAAACAAATGCATATMOGTMCAACACATGCMATGOTC 97 
EMRSA_16.seq - GAAACAMTGCATACAAOGTAAOGACAAATCAAGATGG-- 50 
MRSA_PWH_.seq MGAITCAACAAGOCAAGOG-AAACAAATGCATACAAOGTAAGGACAAATCAAGATGGCA 90 
BRAZILIAN-OOME.SEQ AA(mur--CAAG0CAAG0G-AAACAMTGCATACMa7rMCGACAAATCATGATGGCA 88 
EMRSA一7.SEQ AAGATrcMCACOOCAAGOG-AAACAAATGCATACAAOGTAAOGACAAATCMGATGGCA 99 
EMRSA_4.SEQ AAGATTCAACAOOCmGOG-AAACAAATGCATACAAGGTMCGACAAATCAAGATQGCA 77 
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EMRSA—l.SBQ AAG -CCAAGOG-AMCAAATGCATACMGGTMOGACAMTCAAGATGGCA 5 5 
E M R S A �1 . SBQ MGATrCAACAAGCCATCAG-AAACAMOGCATACAAOnMOGACAAATCAAGATGGCA 8 1 
NY-JAPAN-CLONE.SEO MGATTCMCAAGCCMGTG-AAACAAATGCATACAAOCTMOGACAAATCAAGATGGCA 9 0 
PEDIATRIC-O J ONE.SEQ MGAT-CAACAAGCCAACTGTAAACAAATGCATACAAOCTAAGGACAAATCMGATGGCA 8 9 
EMRSA^l4 .SEQ AA----CMC-•-CCAAGTG-AAACAAATGCATACAACGTAAOGACAAATCAAGATGGCA 6 4 
EMRSA_3 • SBQ AAGGOOCAAG- - -CCAACTG-AAACAMTGCATACAAOGTMOGACAMTCAAGATQGCA 7 6 
EMRSA_13.SEQ AATAOCAGATCAG--- AMCAMOGCATACMOGTAACGACAAATCAAGATGGCA 7 2 
E M R S A _ 1 5 . s e q AAGAOCTCATOC AAACAAACGCATACAAOCTAAOGACAAATCAAGATGGCA 7 0 
EMRSA_9.SBQ GTATGTCTATG GATAGAGmTAAAOTArrnxnTACimGGACCATATGTOG 97 
本 * * • * * • » * * * * * 
IBERIAN-CLONE.seq AAGTATCATACGGAGCTCGTCOGACATACAAGAAGOCAAGOGMACGAATGCATACAATG 1 5 0 
EMRSA一 6 . SBQ MGTATCATACGGAGCrOGTOOGACATACMGMGOCAAGOGAMOGAATCCATACAATG 1 7 7 
EMRSA_12.SBQ MGTATCATACGGAGCrOCTCCGACATACMGMGOCMGGGAAAOGAATGCATACAATG 1 7 8 
EMRSA_2.SEQ - -
EMRSA一 5 . SEQ MGTATCATAOGGAGCTOGTOOGACATACMGMGCCAAGCGAAAOGMTGCATACMTG 157 
EMRSA J 0 . SBQ MCTATCATACGGAGCTOGrTOOGACATACAAGAAGOCAAGOGAAAOGMTGCATACAATC 1 5 7 
E M R S A _ 1 6 . s e q - - -
MRSA__PWH_.seq CAGTATCATATCGaOOGOCCGACACAAAACAAAOCAAGCGAAACAAATGCATACAAGG 1 5 0 
BRAZILIAN-CLONE. SEQ CACTATCATATCGGGCTCGCCOGACACAAMCAAACmGOGMACAAATGCATACAACG 1 4 8 
EMRSA一7 .SBQ CAGTATCATATGCOOOGGCOGACACAAAACAMCmGOGAAACAAATGCATACAACG 1 5 9 
EMRSA_4.SEQ CAGTATCATATGGOGCrOGGCCGACACAAAACAAACCAAGCGAAACAAATGCATACMOG 1 3 7 
E M R S A � . S E Q CAGTATCATATCGOOCmmCACAAAACMAOCAAGOGAAACAMTGCATACAAOG 1 1 5 
E M R S A J l . S E Q CAGTATCATATCGGGCrOGOmCACAAAACAAGOCAAGCAMACMATGCATATAAOG 141 
NY-JAPAN-CLONE.SEO CAGTATCATAOGGAGCKmmCACAAMCAAGOCAACTGAAACAMCGCATATMOG 1 5 0 
PEDIATOIC-OjONE.SEQ CAGTATCATACGGAGCrOGCCCAACACAAAACAAGCCAACTGAMCAAACGCATATMCG 1 4 9 
E M R S A . M . S B Q CAGTATCATACGGAGCrOGOmCACAAAACAAGCmGrrGAMCAAAOGCATATMOG 1 2 4 
EMRSA一 3 . SEQ CAGTATCATAOGGAGCrGGamCACAAAACAAGOCMCTGAAACAAAOGCATATAACG 1 3 6 
EMRSA_13 .SE0 CAGTMCATATGGaOGCTOCAACACAAAACAAGOCAAGCAAAACMAOGCATATMOG 1 3 2 
E M R S A J S . s e q CAGTMCATATGGCGCrOGTCCAACACMAACMGOCAAGCAAAACAAAOGCATATMOG 1 3 0 
EMRSA_9.SEQ C A C T A C C A T - C T G C A T C T C n T - C n T A C m i G T A T G C - A T n m n T A A C T — — T O G C T 1 4 9 
I B E R I A N - C L O N E . s e q TMCAACACATGCAAACGGOCAAGTATCATAOGGAGCTOCTCCGACACAAAACAAGCCAA 2 1 0 
EMRSA_6.SB0 TMCMCACATGCAAAOGGOCAACTATCATAOQGAGCTGCTOOGACACAAAACAAGOCAA 2 3 7 
EMRSA_12.SEQ TAACAACACATGCAMOGGOCAAGTATCATAOGGAGCrCCTCCGACACAMACAAGOCM 2 3 8 
EMRSA_2.SBQ - OCAAGTATCATATCGOOOGCmACACAMACAAGCm 1 5 4 
EMRSA一5.SBQ TMCAACAQVmAAOGGOCMCTATCATAGGGAGCTCGTCOGACACAAMCAAGCCAA 2 1 7 
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EMRSA.IO.SBQ TMCAACACATGCAAAOGGOCAAGTATCATAGGGAGCTOGTOGGACACAAMCMGCCAA 2 1 7 
E M R S A _ 1 6 . s e q CACACTATCATA-CmOOGOOOGACACAAAACAAGOCAA 9 0 
MRSA一PWH一.seq TMCMCACATGCAAAOGGCCAAGTATCATATGGCGOOCGCCCMCATACAAGAAGOCAA 2 1 0 
BRAZILIAN-CLONE. SBQ TMCAACACATGCAMOQGCmGTATCATATQGOGOOOGOOC- 191 
EMRSA_7.SEQ TMCMCACATGCAMOGGCCAAGTATCATATGGCGOOGGOmCATACAAGMGCCM 2 1 9 
EMRSA_4.SE0 TMCAACACATGCAAAOmMGrrATCATATCGammrAACATACAAGAAGOCAA 1 9 7 
EMRSA_1.SFJQ TMCAACACATGCMAOGGOCAAGTATCATATGGOGCOOGOOCAACATACAAGMGCCM 1 7 5 
E M R S A J 1 . SBQ TMCAACACATGCAAAOGGCCAACTATCATATOGOOOGOCOGACATACAACAAGCm 2 0 1 
NY-JAPAN-CLONE.SBQ TMCAACACATGCAMTGCTCAACTATCATACQGTGCTOGamCACAAAAAAAGCCM 2 1 0 
PEDIA'miC-CLONE.SBO TMCAACACATGCAAATGGnmGTATCATAOGCTQCmxmCACAAAACAAGTCAA 209 
EMRSA_14.SB0 TMCAACACATGCAAATGCTCAACTATCATAOGGACOOGCOCGACATACAAGAAGCCAA 1 8 4 
EMRSA_3.SBQ TMCMCACATGCAAATGCTCAACTATCATAOGGAGCKmmCATACAAG--GCm 1 9 4 
E M R S A J 3 . S E Q TMCAACACATGCAMOGGTCMGTATCATACGGAGCrOGTOGGACATACAAGAAGCCAA 1 9 2 
E M R S A _ 1 5 . s e q TMCMCACATC-AMOGGTCAACTATCATAOGGAGCianiOOGACATACAAGMGOCAA 1 8 9 
EMRSA—9.SBQ TGTnTIUKnTGGGOGAGCrCOGTATGACACT-TGACOGrniG-CATGTGGTr-GITAC 2 0 6 
**** * * * ** 
IBERIAN-CLONE.seq GCAAMCAAAOGCATATMOCTMCAACACATGGAAACGGCCAAGTATCATATGGCGCTC 2 7 0 
EMRSA一6.SEQ GCAMACMAOGCATATAAanMCAACACATOGAAAOGGCCAAGTATCATATGGOOC 2 9 7 
E M R S A J 2 . S E 0 GCAAMCAAACGCATATMOGTMCAACACATGGAAACGGCCAAGTATCATATGGOGCTC 2 9 8 
EMRSAJLSBQ GCAAAACAAAOGCATATAAOGTMCAACACATGGAMGGGOCAAGTATCATATGGOGCTC 2 1 4 
EMRSA一5.SEQ GCAAMCAMCGCATATAAOGrrMCAACACATGGAMOGGCCAAGTATCATATGGOGCTC 2 7 7 
EMRSA.IO.SBQ GCAAMCAAAOGCATmAOCTMCAACACATGGAAAOGGCmCTATCATATQGOGCrC 2 7 7 
E M R S A _ 1 6 . s e q GOGAMCAAACGCATATMGGTMCAACACATGCMACGGCCAAGTATCATACGGAGCTC 1 5 0 
M R S A _ P W [ L . s e q GOGAAACMAOGCATACAAOCTAAOGACAAATCAAGATGGCACACTATCATATGGOGCTC 2 7 0 
BRAZILIAN-CLONE.SEQ  
EMRSA_7.SBQ GOGAMCAAAOGCATACAAOCTMOGACAAATCAAGATQGCACACTATCATATGGaOC 2 7 9 
EMRSA_4.SBQ GCGMACMAGGCATACMOGTMGGACAMTCAAGATGGCACAGTATCATATGGCGCTC 2 5 7 
EMRSA一 1 . SEQ GOGAMCAMOGCATACAAanMOGACMATCAAGATGGCACACTATCATATGGOOC 2 3 5 
E M R S A �1 . SEQ CTGAAACAAATGCATACManMOGACAMTGGAGATGGCACAOTATCATATGGOGCrC 2 6 1 
NY-JAPAN-CLONE.SEQ GCAAAACAAATGCATACAACGTAACAACACATGCAMTQCTCAACTATCATATGGOGCTC 2 7 0 
P E D I A T O I C - O O N E . S B Q GCAMACAAATGCATACAACGTAACAACACATGCAAATGGTCAAGTATCATATGGOGCTC 2 6 9 
EMRSA_14.SEQ GOGMACMATGCATACAAOCTMCAACACATGCAAATCCTCAAGTATCATATQGOGCrC 2 4 4 
EMRSA一3.SEQ GOGAAACAMTGCATACAAOGTMCMCACATGCAMTGCniCAACTATCATATQGCGCTC 2 5 4 
EMRSA_13.SEQ GOGMAOGMTGCATATMOCTMCAACACATGCAAAOGCTCAACTATCATATGGOGCTC 2 5 2 
EMRSA.I 5 . s e q GCGAAAOGMTGCATATMOGrrMCAACACATGCAAACGCTCAAGTATCATATGGOOC 2 4 9 
EMRSA一9.SEQ G T T A T A T C O G T K m T O G C r r o G C T - T G n T n j r C T O Q G A G G A C O C n j r A T G A T A a T 2 6 5 
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IBERIAN-CLONE, s e q GCHMC-ACAAMCMGCCMGCAAMCAMTGCATACMOGTAACAAC--ACATGCAA 3 2 7 
E M R S M . S E Q GOCCAAC-ACAAMCAAGOCAAGCAAAACAAATGCATACAAGCTMCAAC--ACATGCAA 3 5 4 
EMRSA_12.SEQ (KITMC-ACAAMCMGCmGCAAMCAMTGCATACMOGTAACAAC-- ACATGCAA 3 5 5 
EMRSA^2,SBQ GCOCAAC-ACAAAACAAGOCAAGCAAMCAAATGCATACAAanMCAAC--ACATGCAA 2 7 1 
EMRSA一5.SEQ GCCCMC-ACAAAACAAG(mGCAAAACMATGCATACMOGTMCMC--ACATGCAA 3 3 4 
EMRSA一lO.SBQ GOCCAAC’ACMAACAAGOCAAGCAAAACAAATGCATACAAanMCAAC“ACATCm 3 3 4 
E M R S A _ 1 6 . s e q GTOCGAC-ACAAMCAAGCmGCGAAAOGMCGCATATMCmMCAAC--ACATGCM 2 0 7 
MRSA_PWH_. s e q GOGOGAC-ACAAAACMGOCAAGOGAAACAAACGCATATMOnMCAAO-ACATGCAA 3 2 7 
BRAZILIAN-CLONE.SEQ …-GAC-ACAAMCMGOCMGOGMACAMCGCATATMOGTAACAAC--ACATGCAA 2 4 4 
EMRSA_7.SEQ GOOOGAC-ACAAAACM(mAGOGAMCAAAGGCATATMa7rAACAAC--ACATGCAA 3 3 6 
EMRSA_4.SEQ GOCOGAC-ACAAMCMGCCAAGOGAAACAAAOGCATATMCGTMCMOC-ACATGCM 3 1 5 
E M R S A �. S E Q GCOCGAC-ACAAAACAAGCCAAGOGAAACAAAOGCATATMOnMCAAC--ACATGCAA 2 9 2 
EMRSA一 1 1 . SEQ GCCOGAC-ACAAAACAAGOCMGCGAAAOGMTGCATATMOGTMCAAC--ACAGGGAA 3 1 8 
NY-JAPAN-CLONE.SBQ GOOOGAC-ACMAAAAAGCCMGCAMACAAATGCATATMOGTMCAAC—ACATGCAA 3 2 7 
PEDIATRIC-CLONE.SEQ GCCCGAC-ACAAAAMAGOCMGCAMACAMTGCATATMOGTMCAAC--ACATGCAA 3 2 6 
EMRSA_14.SEQ GOCOGAC-ACAAAAAAAGCmGCAAMCAAATGCATATMOGrrAACAAC"AQVKm 3 0 1 
EMRSA_3 . SEQ GCCOGAC-ACAAAAAMGOCAAGCAAAACAAATGCATATMOCTMCAAC--ACATGCAA 3 1 1 
E M R S A �3 . SEQ CmCOGAC-ACAAAACAAGGCMGOGMACAMTGCATACAAOGTMCAAC--ACATGCAA 3 0 9 
E M R S A _ 1 5 . s e q (JrCCGAC-ACAAAACAAGGCAAGOGAMCAAATGCATACAAOGTMCAAC--ACATGCAA 3 0 6 
EMRSA一9.SEQ G G O O G T T T G C A T G r K n T G O n T A O T I T A T A T G a n T K n T T O G C I T O G G C m n T n m i G 3 2 5 
氺* * * * • * * ••• 本 
I B E R I A N - C U M . s e q ACGGTCAAGTCTCATAOGGAGCTCGOCGGACATACAAGMGCCAACTAAAACAAATGCAT 3 8 7 
EMRSA一6.SEQ AOGCTCAAGTCTCATAOGGAGCTOGOOOGACATACAAGMGOCAACTAAAACAMTGCAT 4 1 4 
EMRSA_12.SEQ ACGGTCAAGTGTCATACGGAGCTOGCOOGACATACAAGMCmACTMAACMATGCAT 4 1 5 
EMRSA_2.SBQ AOGGTCAAGTGTCATAOGGACOOGOOOGACATACMGMGOCAACTAAAACAAATGCAT 3 3 1 
EMRSA一5.SEQ AOGGTCAACTCTCATAOGGAGCTCGCOOGACATACMGMGOCMGTMAACAAATGCAT 3 9 4 
EMRSA_10.SBQ AOGGTCAAGTGTCATAOGGAGCKmmCA-ACAAGMGOCAACTAAAACAAATGCAT 3 9 3 
EMRSA一16.seq AGGCTCAAGTGTCATAOGGAGCrGGCOCAACACAAAACMGOCAAGTAAAACAAATGCAT 2 6 7 
MRS/L_PWH_. seq AOGGCCAAGTATCATAOGGAGCTOGTOOGACACAAMCAAGCCAAGGGAAAOGAAOGCAT 3 8 7 
BRAZILIAN-CLONE.SEQ AOGGCCMGTATCATACGGAGCTOGTCGGACACAMACAAGCCAAGGGAAACGMOGCAT 3 0 4 
EMRSA一7.SEQ AGGGOCAAGTATCATAOGGAGCTOGTOOGACACAAAACAAGCmGOGMACGMOGCAT 3 9 6 
EMRSA—4.SEQ AOGGCCAAGTATCmCGGAGCrGGTOOGACACAAAACAAGCCAAGOGAMOGMGGCAT 3 7 5 
EMRSA—l. SEQ ACGGCCAAGTATCATAOGGAGCTOCTOOGACACAAAACAAGOCAAGOGAAAOGMOGCAT 3 5 2 
E M R S A �1 . SEQ ATCGCCAAGTATCATATGGGGCTOGTCGGACACAAAAGMGOCMGCAAAACAMTGCAT 3 7 8 
NY-JAPAN-CLONE.SEQ ATGCTCAAGTATCATAOGGAGCrOGOOOGACATACAAGMGOCAAGOGAAACAAATCCAT 3 8 7 
PEDIATRIC-CLONE.SBO ATGGTCAACTATCATAOGGAGCrOGOOOGACATACAAGMGOCAAGOGMACAMTCCAT 3 8 6 
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EMRSA-14.SEQ ATGGTCAAGTATCATAOGGAGCTCGOOOGACA-ACMGMGOCAAGOGAMCAMTCCAT 360 
E M R S U . S E O ATGGTCAAGTATCATAOGGAGCrOGCCOGACATACMGMGCCAAGOGAMCMATGCAT 371 
EMRSA_13.SEQ ATGGTCAAGTATCATATGGOGCrGGTOOGACACAMACAAGCCMGCAAAACAMOGCAT 369 
EMRSA_15.seq ATGGTCMGTATCATATOGOGCTOCTOOGACACAAAACAAGOCAAGCAAAACAAAOGCAT 366 
EMRSA_9.SEQ TOGGGOGAGOGCCATATCATACrCTGCCATCTroATIUrGTOGmanTGTATCOGnT 385 
• * * ** ** * 本 本 j)： 
IBERIAN-CLONE.seq ACAATGTMCAAC-ACATGCA-GATGGTACTCOGACATATGG——GCCTAGAGTAACA 440 
EMRSA一6.SEQ ACAATGTAACMC-ACATCCA-GATGGTACTGOGACATATGG……GOCTAGACTAACA 4 6 7 
EMRSA_12.SEQ ACMTGTMCMC-ACATGCA-GATGGTACTGOGACATATGG……GCCTAGACTAACA 468 
EMRSA一2.SEQ ACMTGTMCMC-ACATGCA-GATGGTACTGGGACATATGG——GOCTAGACTAACA 384 
EMRSA_5.SEQ ACAATGTAACMC-ACATGCA-GATGGTACTGOGACATATGG——GOCTAGAGTAACA 447 
EMRSA—10.SEQ ACAATGTMCAAC-ACATGCA-GATGGTACTGOGACATATGG……GOCTAGACTAACA 4 4 6 
EMRSA_16• seq ACMTGTMCMC-ACATGCA-GATGGTACTGOGACATATGG——TCCTAGAGTAACA 320 
MRSA_PWH_ . seq ATMOGTMCAAC-ACATGCA-AAOGGTCMGTCTCATAOG-AGCTOGOmCACAAAA 444 
BRAZILIAN-OXM.SEQ ATMGCTMCAAC-ACATGCA-MOGGTCMCTGTCATAOGGAGCTCGCCCAACACAAM 362 
EMRSA_7.SEQ ATMaTrMCAAC-ACATGCA-MOGGTCAAGTCntATAOGGAGCrOGamCACAAAA 454 
EMRSA_4.SEQ ATMOGTMCAOC-ACATGCA-MCGGTCAAGTCTCATAOGGAGCTCGCCCMCACAAAA 4 3 3 
EMRSA一1 .SEQ ATAAOCTMCAAC-ACATGCA-MOGCTCAACTCTCATAOGGAGCTOGamCACAAAA 4 1 0 
EMRSA J 1 . SEQ ATMajrMCAOC-ACATGCA-MOGGCCMGTATCATATGGOGCTGGTCOGACATACAA 436 
NY-JAPAN-CLONE. SEQ ACMOGTMCAAC-ACATGCA-MTGCTCAAGrrATCATATGGCGCTOGCCOGACACAAAA 4 4 5 
PEDIATRIC-OONE.SEQ ACAACGTMCAAC-ACATGCA-MTGGTCAAGTATCATATGGOOCGCCOGACACAAAA 4 4 4 
EMRSA^H.SEQ ACAAOGTMCMC-ACATGCA-MTGCTCCACTATDVTATCG-GOCTOOOOGACACAAAA 4 1 7 
EMRSA一3.SEQ ACAACGTMCAAOCACATGCA-MTGGTCMGTATCATATGGOOOGCOCGACACMAA 430 
EMRSA_13.SEQ ATMOGTAACAAC-ACAOGGA-AATCGOCAACTATCATAOGGAGCTOGCOOGACATACAA 427 
EMRSA_15. seq ATMOGTMCAAC-ACAOG-A-MTGGOCAAGTATCATAOGGAGCTOGCCOGACATACAA 423 
EMRSA_9.SEQ GTTTOGCrrOGGCnunUTATCrniGGGOGGGOGOCATATCATAaTGGOOG“TrK]CA 443 
» * * * * * •• » 本 本 本 氺 》 * * 
IBERIAN-CLONE.seq AAA--TAACmT--GrTAACTC 4 5 7 
EMRSA_6.SBQ AAA--TAAGTIT--GTAACIUTATCCAAAG ACATACAGTCTATACAAAA-OG 514 
EMRSA_12.SEQ AAA--TAAGTIT--CTAACrCTATOCAAAG ACATACAGTCAATACAAAA-CA 515 
^SA_2.SBQ AAA--TAACnTT--GrrAACIUTATOCAAAG ACATACACHmTACAAAA-CA 431 
EMRSA_5.SEQ AAA--TAAGTIT--GTAACTCTATOCAAAG-- ACATACAGTCAATACAAAAACA 495 
EMRSyUO.SEQ AAA--TAAGnT--GTMCTCTATOCAAAG-------ACATACAGTCMTACAAM-CA 493 
EMRSA_16.seq AAA--TAAGTIT--ATAACTCTATCjCATAG ACATACAGTCAATACAAAA-CA 367 
MRSA_PWH_.seq CAAGOCMGT-AAAACAAATGCATACAATCTMCAAC-ACATGCAGATQCTACKJOGACA 502 
BRAZILIAN-OXM.SBQ CAAGOCAACT-AAMCAAATGCATACAATCTMCMC-ACATGCAGATOCTACrcOGACA 420 
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EMRSA一7.SEQ CAAGCCAAGT-MAACAMTGCATACAATGTMCAAOCACATGCAGATGGTACTGGGACA 513 
EMRSA_4.SE0 CAAGCCAAGTTAAAACAMTGCATACAATCTMCAAC-ACATGCAGATGGTACTGOGACA 492 
EMRSA—l.SBQ CMGCCMCT-AAAACAAATGCATACAATGTMCAAC-ACATGCAGATGCTACTGOGACA 468 
EMRSA.l 1. SBQ CMGCCAACT-MAACAAATGCATACMTCTAACAAC-ACATGCAGATGGTACrGOGACA 494 
NY-JAPAN-CLONE.SEO AMGCCMGC-GAMCAAAOGCATATMGCTMCMC-ACATGCAGATGCTACrGOGACA 503 
PEDIATOIC-OjONE.SBQ MAGOCMGC-GAAACAAAOGCATATManMCAAC-ACATGCAGATGCTACTGGGACA 502 
EMRSA_14.SEQ AAAGOCMGC-GAMCAAAOGCATATAAOOTMCAACCACATGCAGATGGTACrGOGACA 476 
EMRSAJ .SBQ AAAGCCAAGC-GAAACMAOGCATATMOrrMCAAC-ACATGCAGATGCTACrGOGACA 488 
EMRSA_13.SEQ GMGOCAAGC-GAAACAMTGCATACAATCTMCAAC-ACATGCAGATGGTACTGOGACA 485 
EMRSA_15.seq GMGCCAAGC-GAAACAAATGCATACMIUrMCAAC-ACATGCAGATCGTACrcOGACA 481 
EMRSA_9.SEQ IXjIUIT--GTT---AOCTATCTrATCmTGTKnT-TOGaTGCAGTriUrn.lCTGTC- 496 
* 
IBERIAN-CLONE.seq  
EMRSA_6.SEQ GTAOGT-TCnTA-CAACAG--TAT - - 535 
EMRSA_12. SEQ maJTATCnTA-CAACAG- -TAATCATGCA-TTCTAT- - -GATGCITCrAACrGAATr 568 
EMRSA_2.SEQ TTAOGTATCnTA-CAACAG--TAATCATGCA-TTCTAT---GATGCmCTAACnGAATr 484 
EMRSA一5.SEQ TTAOGTATCnTA-CAACAG--TAATCATGCA-TTCTAT---GATGCnUTAACTGAATr 548 
EMRSA_10. SEQ TTAOGTATCnTA-CMCAG--TAATCATGCA-TTCTAT- - -GATGCnurAACTGAATr 546 
EMRSA_16. seq TTATGTATCnTA-CAACAG- -TAATCATGCT-ITCrAT- - -GATGCnUTAACTGAATr 420 
MRSA—PWH_. seq -TATGGTXCTAGACTMCAAMTMCnTTATAACrC - - 537 
BRAZILIAN-CLONE.SEQ -TATGCmrTAGACTAACAAAATAAGTITATAACrC 455 
EMRSA—7.SEQ -TATGGTOCTAGACTMCAMATMCnmTMCrCTATOCATAGACATACACTCAATAC 572 
EMRSA一4.SEQ -TATGGrCCrAGAGTAACAAAATAAGnTATMCrCTATOCATAGACATACACTCAATAC 551 
E M R S A j . SEQ -TATGGTOCTAGACTMCMMTAACmTATAACrcTATOCATAGACATACACTCAATAC 527 
EMRSA」1. SEQ -TATGGTOCTAGAGTAACAMATMGnTATMCimTOCATAGACATACAGrcAATAC 553 
N Y - J A P A N - O j O N E . S B Q -TATGamAGACTAACAAAATAAAriTATAACrC- - - - - 538 
PEDIATRIC-CLONE. SEQ -TATGGGCCrAGACTAACAAAATAAATITATA-TTC 536 
EMRSA_14.SEQ -TATGGGCCTAGAGTMCMAATAAATITATMCrCTATOCAAAGACATACACnmTAC 535 
E M R S A J . S E Q -TATGGGCmGAGTMCAAAATMATrTATAACrCTATOCAMGACATACA( JKMTAC 5 4 7 
EMRS[13 .SBQ -TATGGGOCTAGAGTMCAAAATAAGTnurAACrCTATCmAGATATACAGrrcAATAC 544 
EMRSA一 15 . seq -TATGGGCCTAGAGTAACAAAATMGnTGTMCimTCCAAAGATATACACnunTA- 539 
E M R S O . S E Q …-GGGC---GAGOGOCATA-TGA---TAaUTGOCATCIT--GATnUTCGrrAOTrT 543 
IBERIAN-CLONE.seq  
EMRSA一6.SBQ  
EMRSA^12.SEQ AAA-GCATOG--- AACAA---- 582 
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EMRSA_2.SEQ AAA-GCATCjG AACAATCGG 502 
EMRSA_5.SEQ AAA-GCATOG -A 558 
EMRSA—10.SEQ AAA-GCATOG AACAAT--- 561 
EMRSA_16.seq  
MRSA_PWH_.seq  
BRAZILIAN-CLONE. SEQ  
EMRSA_7.SEQ AA 574 
EMRSA_4.SE0 AAA-OGTTATCTrATCrTTACAACAGTA- 577 
EMRSA」.SEQ AAA-ACATTATGT-TCnTACAACACTr--- 552 
EMRSA-11. SEQ AAA-ACATTA- - -CTCnTACAACACTATC 579 
NY-JAPAN-CLONE.SEQ  
PEDIATRIC-OJONE .SEQ  
EMRSA_14.SEQ A 536 
EMRSA_3.SEQ AAA-GAAmTGTATCTATACAACACT--- 573 
EMRSA_13.SEQ AAA-ACA 550 
EMRSA_15.seq  
EMRSA一9.SEQ CTATGCATT-TGTnOO-TGGCTrGGGA 571 
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a T e E D O T e G T o S E 
OTeCiGFED OTeGFToER 
OTeCiGFE 
ONCiGToSECD 0=Oxacillin, T=Tetracyc]ine, M^Mupirocin, 
0 N=Netilmicin, Ci=Ciprofloxacin, G-Gentamicin, 
0 F=Fusidic acid, To=Tobramycin, S=Co-Trimoxazole, 
O T*eTo E 





Details of MRSA isolates selected for AFLP, Phage typing and MLST 
UMi f " " 9 2 丫 「 P F Q E PFQE (.ub) Stock no. Yr Source Abg Abg (»ub) PFGE PFGE (sub) 
UN15 93 BC A A U 00^0917 00 BC A  
94/6492 94 B C A A 1 j _ 90 B C C 10 C 3a 
94/8190 94 BC A A l a UN8 91 B C C 68 U D 3b 
95/0750 95 BC A E 93/0060 93 B C C 47 A 2b 
96/6303 96 B C A A 1a 95/0230 95 B C C 47 A 2h 
llZll ll ： aC l a 96/0708 96 B C C 24 U A 
l l n l o l 98 BC ： ： 9 则 1 97 B C C 10 A 1b 
98/2562 98 B C A A 2c 97/5406 97 B C C 40 U H 
9 8 / 3 6 3 0 98 B C A A 1b 9 8 / 5 018 9 8 B C C 1 D 1a 
99/4178 99 BC A D 6 99/2161 99 B C C 5 U A 1b 
00/1469 00 BC A A 2f 99/3166 99 B C C 21 U B 4 
二 二 二 l l Z r A C 1a 00/1232 00 N B C C 53 U C 5 
二 二 ：： = ： ： ；ob 00/2385 00 N B C C 39 F 1 
94/5733 94 N B C A A I d 00^3159 00 N B C C 61 U A 9 
94/7257 94 N B C A C 1a 00/3202 00 N B C C 2 3 U B 8 
95/0580 95 N B C A A l a 93/0141 93 N B C B 9 D I d 
96/0487 96 N B C A C 1a 93/0787 93 N B C C 6 6 U C 1b 
96 N B C A A 7 93/1073 93 N B C C 44 D 2 
9 川 719 97 N B C A A 1f 94/2481 94 N B C r 7 ^ Z 
97/5903 97 N B C A A 2 a 94 N B C B 9 A 2e 
98/1748 98 N B C A A 2a 9 m U 2 94 N B C C 44 A 2a 
98/3266 98 N B C A A 2b 94/6242 94 N B C C 11 U A 3 
99/4027 99 N B C A D 1a 94/7565 94 N B C C 54 U D 3a 
99/4915 99 N B C A A 5a 94/7780 94 N B C C 58 U A 4a 
= 。 92 BC B 8 A l a 95/1719 95 N B C A A 4a 
00/0254 00 B C B 2 A 6 9 5 / 3 0 4 3 9 5 n b ^ ^ ： 二 
00/0860 00 BC 8 2 » 2r yS/JlWJ 95 NBC C 10 A 3 
00/2016 00 B C B 1 D 3a ®5/3470 95 N B C C 18 A 1b 
00/2436 00 BC B 8 A 2a 95/4987 95 N B C C 27 U B 10 
95/5136 95 B C B 5 B 1a 96/1292 96 N B C C 2 9 U B 6 
95/5355 95 BC B 8 A l i 96/2209 96 N B C C 25 B 3 
96 B C B 4 B l d 96/5689 96 N B C C 18 A l b 
= 二 二 二 bB e B 1a 画 5 9 6 N B C C « J ；： 
97/0509 97 BC B 4 b la 97/0080 97 NBC C 50 A 1a 
97/0533 97 BC B 5 B 11 97/0130 97 N B C C 34 U C 6 
97/0771 97 BC B 7 C 1b 97/0156 97 N B C C 64 A 1e 
98/1699 98 B C B 5 B 1a 97/0717 97 N B C C 50 C 2a 
99 B C B 8 A l a 97/6132 97 N B C C 35 U C 3a 二 : ; ： r _ 5 6 98 NBC C 31 U P f 
00/1063 00 N B C B 4 B l a ^8/1120 98 N B C C 3 C 4 
00/1319 00 N B C C 22 B l e 99/4522 99 N B C C 14 H 
00/2854 00 N B C B 4 G 99/2611 99 N B C A C 7 
95/0133 95 NBC B 2 A 1g 88/15204 88 NBC C 83 U A 2a 
95 N B C B 5 B 2 88/17625 88 N B C C 81 D 1a 二 = ：： ；：!^ i ^ : 6 隱 3 0 1 88 NBC C 84U A 二 
96/7557 9 6 N B C B 4 B i b 89/8228 89 N B C C 87 D 1c 
97/4897 97 N B C B 8 C 3b 89/16629 89 N B C C 88 U A 2a 
9 8 / 0 4 8 4 98 N B C B 5 B 9 89/23410 89 N B C C 46 U D 4 
98/0974 98 N B C B 2 C 3a 89/36765 89 N B C C 82 U D 5 
l l ' l l l l 98 N B C B 5 F 3 89/51355 89 N B C C 81 F 2 二 ^ ^ ^ 90 NBC B 9 C ；c 
99/2868 99 N B C B 6 A 2a 90/15781 90 N B C C 78 U E 
99/2922 99 N B C B 5 G 90/21136 90 N B C A A 5b 
99/3937 99 N B C B 5 B 1c 90/36765 90 N B C C 81 D 1b 
99/4729 99 N B C B 3 A 2c 90/90753 90 N B C C 10 C 2b 
00/0917 00 BC C 6 A 1a UN6 91 B C C 4 9 A ？ r i 
t! 二 = g ^ ^ - _ 1 6 91 NBC C ：： ； 
93/0060 93 B C c 47 A 2b 91/32131 91 N B C C 79 U C 1a 
95/0230 95 B C C 47 A 2b 91/34268 91 N B C A C 2a 
96/0708 96 BC C 24 U A 4b 91/41429 91 N B C C 4 9 A I k 
9 7 / 4 1 1 1 97 B C C 10 A 1b 91/52922 91 N B C C 74 A 4a 
97 B C c 40 U H 91/68626 91 N B C C 44 A l a 
= 二 二 C 1 0 13 9.94987 91 NBC C 94 U S ；S 
99/3166 99 BC c 21 U B I 92/14533 92 NBC C 93 A 1e 
00/1232 00 N B C C 53 U C 5 92/41378 92 N B C C 75 U A 1c 
00/2385 00 N B C C 39 F 1 92/92611 92 N B C C 10 C 1a 
0 0 / 3 1 5 9 0 0 N B C C 61 U A 9 93/15626 93 N B C C 3 A I d 
00/3202 00 N B C C 23 U B 8 93/38414 93 N B C A E 
= 二 二 ^ L u ^ ；^  93^ 20149 93 NBC C 93 A 1c 
9 3 / 1 0 7 3 93 N B C C 44 D 2 
9 4 / 2 4 8 1 94 N B C B 9 A 2e 
9 4 / 4 1 1 2 94 N B C C 44 A 2a 
9 4 / 6 2 4 2 94 N B C C 11 U A 3 
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